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ABSTRACT
Enterohepatic Helicobacter (EHH) species are gram-negative bacteria, which are
poorly studied. Several studies suggest that EHH species contribute to inflammatory bowel
disease IBD in humans. IBD and colorectal cancer (CRC) has emerged as a public health
challenge worldwide. Indole-3-carbinol (I3C) is one of the natural dietary indoles abundant
in Brassica (cruciferous) vegetables. The aryl hydrocarbon receptor (AhR) plays an
essential role as a regulator by controlling the balance between Tregs and Th17 cells. The
activation of AhR by ligands derived from food or intestinal microbiota is an essential
control mechanism in that balance. Moreover, many studies showed indoles achieving
chemo-preventive effects against cancer.
We used the dextran sulfate sodium (DSS)-induced colitis mouse model to study
the role of Helicobacter muridarum (Hm) bacteria with and without I3C treatment. We
focused on the pathology outcomes after the bacterial infection and the I3C treatment
during the DSS course. Weight loss, diarrhea, blood in the stool, and histopathology were
measured. Inflammation markers were also measured in the plasma and the colon. We then
studied the miRNA response. miRNAs are non-coding RNAs that can regulate genes
involved in the immune responses.
The purpose of the second study was to study the role of Helicobacter hepaticus
(Hh). (Hh) can cause colitis in genetic or pharmacologically induced deficiencies of the
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Interleukin-10/Interleukin-10 receptor. We studied (Hh) infection role, in the DSS colitis
model and AOM (Azoxymethane) /DSS colon cancer model in wild-type mice.
Finally, the last study's purpose was to examine the effects of different species of
Helicobacter on developing acute gut injury in male and female mice with and without
DSS treatment. The species used are known to infect humans: H. cinaedi, H. fennelliae, H.
hepaticus, and H. pullorum. Similar pathology and immune response measurements were
done for this study, as was done for the other studies.
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CHAPTER 1

INTRODUCTION
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1.1 Definition and history
Ulcerative colitis (UC) is a disease of mucosal inflammation limited to the colon,
usually characterized by bloody diarrhea, and abdominal pain. UC was the primary subtype
of inflammatory bowel disease (IBD) to be described as a distinct entity [1]. Moreover,
colorectal cancer (CRC) was first recognized as a complication of inflammatory bowel
disease (UC) by Crohn and Rosenberg in 1925 [2]. Since then, a multitude of
epidemiologic studies has confirmed this elevated risk. The exact magnitude of the change
remains an issue of dispute because of numerous biases and method errors in reviewed
studies [2].
Colitis has been recognized as a clinical entity for a very long time. There are
reports by physicians of chronic diarrhea dating back to Greek antiquity. Even Hippocrates
(~ 460–370 BCE) mentioned the various etiologies of diarrhea [3]. The prominence of
inflammation of the gut was featured in many early nineteenth-century medical colleges.
Both François-Joseph-Victor Broussais and John Brown posed the theory that all diseases
derived from inflammation in the digestive tract. This theory arose from an increase in the
anatomical investigation and the use of the microscope at this time. Also, waves of cholera
spread across the globe in the nineteenth century, drawing attention to infectious causes of
diarrhea [2].
Sir Samuel Wilks was the first physician who used the term “ulcerative colitis” in
a case report written in 1859 to explain what is known as UC today [3]. Reports of
comparable cases of a severe and chronic diarrheal illness that did not appear to be of
infectious origin accumulated over the second half of the nineteenth century [3]. In 1888,
Sir William Hale White of London published a description of cases he had seen of
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“ulcerative colitis” that defied any other known causes, like “dysentery, tubercle, enteric
fever.” From this report, the term “ulcerative colitis” entered into the final medical
vocabulary [3].
In the decades following 1909, the medical community's understanding of UC grew
in leaps and bounds [3]. This era included Lewisohn's careful demonstrations of familial
predisposition; Hewitt's association between UC and polyps; and Wangensteen's
recognition that it diagnosed as colon cancer [2]. The first report of UC in children came
in 1923 by Helmholz, which included children from ages eight to fifteen. Advances in
treatment, like ileostomy and blood transfusion, were proposed and later validated as
therapeutic measures helpful for patients with UC [2].
1.2 Symptoms, Etiology, and Epidemiology
UC includes a diffuse mucosal inflammation restricted to the colon. It involves the
rectum in about 95% of cases and will extend proximally in an asymmetrical,
circumferential, and uninterrupted pattern to include parts or all the colon. The hallmark
clinical symptom is bloody diarrhea, usually with apparent signs of rectal urgency and
cramping. The main clinical course of UC includes exacerbations and remissions of the
symptoms [1].
Ulcerative colitis diagnosis was established by the following criteria: the medical
history of the patient symptoms, barium enema imaging, and the appearance during
sigmoidoscopy (in acutely ill patients, proctoscopy was regarded as sufficient), and finally,
the absence of known pathogens in the stools [4].
The bottom-line cause of IBD is still unknown. Several etiological theories for the
UC etiology are presently under investigation. Most investigation areas classify the causes
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of immunogenetic and environmental aspects. However, the rate for IBD in monozygotic
twins does not exceed 50%, highlighting the importance of environmental factors [5-7].
However, all the etiological factors are related to UC within the context of immunological
mechanisms, i.e., cytokine proliferation, mutation of immunologically relevant genes, and
inflammatory mechanisms. Besides, various dietary factors and food particle intake and
colonic microbiota are strong bioactive elements in the etiology of the disease [8].
Inflammatory bowel disease has emerged as a public health challenge worldwide.
In North America and Europe, over 1.5 million and 2 million people suffer from the
disease, respectively [9]. Moreover, more than 0.3% of the population in developed
countries and a growing number of persons in recently industrialized countries in Africa,
Asia, and South America, contribute to an increasing worldwide burden of this disease [9].
On the other hand, colorectal cancer (CRC) represents severe health and social burden
around the world, being the second most common cancer in women and also the third most
common in men [10]. The highest CRC incidence rates occur in Europe, North America,
and Oceana (>40 per 100,000), while Subsaharan Africa has the lowest incidence of this
disease (<2 per 100,000) [11]. Developing regions that have undergone industrialization
and urbanization have seen a significant increase in CRC prevalence. Suggesting that the
adoption of a “Westernized“ diet and/or lifestyle can be a contributory factor [12, 13].
1.3 Immunopathology of ulcerative colitis
The healthy intestine is protected by both an effective mechanical barrier and the
immune system. The inner mucus layer offers protection by preventing large particles from
contacting the epithelial layer while allowing small molecules to pass. The Mucus secretion
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reduction that leads to the thickness of the mucous layer reduction, the increase in
macrophage abundance, and reduce the germicidal are the main colitis features. [8]
Areas of acute inflammation are mostly devoid of the mucus layer [8]. The
proliferation of the enteric epithelial tissue is enhanced, resulting in crypt elongation and,
thus, significant epithelial hyperplasia. One vital cytokine contributing to intestinal health
is Interleukin-22, produced by T helper cells, innate lymphoid cells, and neutrophils [8,
14]. Goblet cells are a frequent cell type in the colonic epithelial tissue during homeostatic
conditions. In colitis, elongated crypts in inflamed areas usually show a loss of mucin and
altered goblet cell morphology [15].
During colitis inflammation, many transcription factors, including signal transducer
and activator of transcription (STAT) 3, STAT1, and nuclear factor-κB (NF-κB), operate
as relevant regulators of inflammatory factor production and infiltration of inflammatory
cells [14]. The pathogenic Th1/Th17 cell populations, on the other hand, expand in the
setting of IBD and express TNF-α, IFNγ, IL-17A, and IL-17F. Their differentiation is
directed by the transcription factor Rorc [16]. Effector T cell responses are controlled by
regulatory T cell (T reg) populations. There is ample evidence that Foxp3-positive
regulatory T cells are capable of suppressing pathogenic effector T cell responses in the
intestine [17]. Additionally, IL-10-expressing Treg cells can effectively resolve
lymphocytic inflammation in the gut [18], as shown in the adoptive transfer model of
colitis. Clinical studies are underway to analyze the efficacy of autologous ex vivo
expanded regulatory T cells in ulcerative colitis [19, 20].
Chronic inflammation and mucosal injury will trigger uncontrolled healing
responses, leading to tissue dysfunction, and ending in carcinogenesis [21]. The potential
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physiological effects of IL-17A to promote carcinogenesis in the colon are followed by
many sequences like the mechanical barrier defect, colon bacterial translocation to the
colon epithelium. Additionally, IL-23 production by innate immune cells, such as dendritic
cells and macrophages, these sequences will activate IL-17A, which in turn can favor
intestinal tumorigenesis [22]. IL-17A producing cells were found in the human colon, and
high IL17A mRNA expression correlates with a poor prognosis in these patients [23-25],
which is another evidence of the role of IL17 in colon cancer. These results may not
indicate a potential therapeutic benefit of targeting IL-17A; however, because of the
different functions of Th17 and further research is needed before initiating clinical trials.
1.4 Role of Enterohepatic helicobacter species (EHH) during colitis and colon cancer
The GI tract harbors massive numbers of bacteria. These bacteria have colonized
the intestine after birth and may weigh between 1 and 2 kg in an adult [26]. This
microorganism ecosystem consists of bacterial, fungal, and viral parts. In some people,
parasites and helminths populate the human gut. Many studies have shown the role of
different bacteria in changing the bacteria decomposition and the metabolic balance of the
microbiota that could harm the mucosa directly and affect the IBD prognosis [8, 27]. For
example, the Segmented filamentous bacteria (SFB), can induce Th17 in mice.
Accordingly, Th17 cells are mainly located in this part of the intestine under physiological
conditions [28]. Citrobacter rodentium and Escherichia coli are another examples for
bacteria that can induce an inflammation the mucosa through the production of serum
amyloid A from epithelial cells followed by releasing the pro-inflammatory cytokines IL6, TGF-β, and IL-1β from dendritic cells, which leads to differentiate Th cells to Th17
cells [28-30].
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Helicobacter spp. are gram-negative, spiral bacteria, which normally grow under
microaerophilic conditions [31]. The general interest in Helicobacter species as potential
triggers of inflammatory disorders was spurred with the identification of Helicobacter
pylori as the etiopathogenic agent of gastritis and peptic ulcer disease in patients in the
early 1980s [32]. Subsequently, an increasing number of Helicobacter species were isolated
from different species. Based on their tropism, Helicobacter spp. can be broadly divided
into gastric (e.g., H. pylori) and enterohepatic species (e.g., H. hepaticus, H. bilis, H.
typhlonius). The genus, so far, includes at least 20 formally named Helicobacter spp.,
characterized based on 16S rRNA analysis, complemented by biochemical, molecular, and
morphological characteristics. At least 11 of these Helicobacter species have been
described to colonize the lower gastrointestinal tract [33].
It is well established that Helicobacter pylori have a wide range of virulence factors
that distress the epithelial regeneration and sustains disease and inhibits mucosal healing
during gastric ulcers [34]. Due to the low pH and digestive enzymes in the stomach, the
diversity of the luminal flora is limited, and H. pylori are one of the few species capable of
colonizing the stomach. Moreover, Th17 cells have a crucial role in colitis development in
both humans and mouse models [35, 36]. H. pylori are known to induce a Th17 response
in the gastric mucosa [37-39], yet H. pylori infection is associated with a decreased risk of
IBD [40]. H. pylori only colonize the gastric mucosa, meaning that any effects of H. pylori
on the colon are likely due to the systemic effects of infection. Furthermore, EHH species
lack the major H. pylori virulence factors cagA and vacA. Thus, one cannot assume that
mucosal or immune effects of H. pylori infection will match those caused by EHH species.

7

It is, therefore, necessary to use infection with EHH species to investigate potential
mechanisms of EHH-mediated contributions to IBD.
Another point of view, In colitis, the colon harbors a plethora of microorganisms,
that acquire direct contact with damaged tissue and regenerating epithelia [41]. Several of
the microorganism species and their virulence factors are not sufficiently characterized; so,
their influence on tissue healing remains speculative. Recent years have seen a vast range
of studies on the intestinal microbiome in colitis and different inflammatory bowel
conditions [42, 43]. Helicobacter species, for example, are associated with chronic
inflammation and the development of cancer [44, 45]. Chronic infection by Helicobacter
spp. in immunocompetent hosts will cause subclinical illness. That will manifest with overt
clinical signs and pathology during immunocompromised states. Most Helicobacter spp.
are isolated from animal reservoirs and cause diseases in some mice. Also, experimental
and spontaneous animal models have shown that infection by EHH will induce
gastrointestinal, hepatic, and biliary tract inflammatory pathology and cancers [44, 45].
There is a risk that analogous to H. pylori infection, EHH could instigate human
inflammatory bowel disease, large intestine cancer, and hepatobiliary illness [46, 47].
However, few studies have examined the mechanisms of colonization and virulence factors
in EHH.
The genomes of several EHH have now been sequenced extensive variations in
gene structure, and content between H. pylori and H. hepaticus were discovered [48],
suggesting that necessary distinctions underlie the different colonization locations and
pathogenic potentials. Helicobacter hepaticus is shown to induce particularly severe types
of colitis in mice with defects in cytokine or T-cell functions [49-53]. Helicobacter bilis
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[54] have been reported to cause colitis mice, whereas Helicobacter cinaedi and
Helicobacter fennelliae are related to colitis in humans [55-58]. However, we do not have
a clear picture of their roles in pathogenesis, and not much is known about the
environmental and host factors that could increase their pathogenesis.
Helicobacter muridarum was initially described as a member of the flora of
conventional rodents [59]. Subsequent studies, however, showed that H. muridarum could
induce colitis and gastritis in mice, suggesting a definite pathogenic role for this bacteria
[60-62]. While Helicobacter hepaticus has been documented to cause colitis in certain
immune-deficient mouse strains [49, 50, 52, 53, 63], Danne, C. et al. study show that
H.hepaticus can produce anti-inflammatory reaction through inducing macrophage IL-10
[64]. Mo Xu. et al. 2018 demonstrated that H.hepaticus could induce tolerance to the gut
pathobiont through T-regulatory cell activation [65]. A current meta‐analysis has
additionally found a significant association between EHH infection and IBD status in
human patients; but, which specific Helicobacter spp. Are linked to human IBD stay to be
elucidated. On this project, we tried to uncover the roles of five species of EHH during
ulcerative colitis.
1.5 Indole -3- carbinol treatment, and AhR Receptors
The environmental factors and a dysregulated immune system are the main
components of IBD pathology. So far, the primary therapeutics broadly available to treat
IBD is based on suppressing the immune response, and the management of symptoms
could leave less active or smoldering disease (i.e., subclinical inflammation or mucosal
barrier dysfunction), risking future relapse [66]. In other words, these therapies are unable
to reset the intestinal homeostasis and do not directly treat the underlying cause of chronic
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inflammation. Therefore, IBD patients require lifelong treatment, and in 10% –15% of
patients, UC can ultimately lead to colectomy [67]. Despite improved treatments, like antiTNF therapy [68], long-term colectomy rates have not declined, highlighting the necessity
for new therapeutic methods.
It has been shown that indole-3-carbinol (I3C), a dietary compound from green
vegetables, maintains a large population of lymphocytes, the intraepithelial lymphocytes
(IELs), in the intestine. IELs express very high levels of the aryl hydrocarbon receptor
(AhR), a member of the essential helix-loop-helix family of transcription factors [69]. I3C
comes from the break-down of the glucosinolate glucobrassicin in the Brassica genus
plants. Under acidic conditions, undergoes condensation and dimerization to form 3,3diindolylmethane (DIM) [70]. AhR is directly activated by DIM and I3C. I3C supports
the survival of IELs and also the organogenesis of lymphoid structures in the
gastrointestinal tract [71]. Moreover, AhR plays an essential role as a regulator by
controlling the balance between Tregs and Th17 cells [72, 73]. The activation of AhR by
ligands derived from food or intestinal microbiota is an essential control mechanism in that
balance [74, 75]. Although AhR is expressed in the early stages of Th17 cell differentiation
[76],

AhR expression is not essential for Th17 cell differentiation. However, it is

nonetheless required for the secretion of IL-22 by Th17 cells, a cytokine vital for the antimicrobial properties of Th17 cells [77-79]. In this project, we are interested in studying the
mechanisms underlying the anti-inflammatory properties of I3C. Given that I3C and other
AhR ligands have an influential role in both miRNAs, and that EHH infection could make
a difference in the incidence of UC and colon cancer, further investigation into the relative
effects of each is warranted.
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1.6 Summary
As discussed, EHH contributes to chronic colon inflammation in mice and could
have a role during ulcerative colitis and colon cancer in humans. However, not all the
species of EHH have been studied experimentally to illustrate the exact role of these
bacteria during the inflammatory bowel diseases and colon cancer. On the other hand,
many studies show the role of I3C as an anti-inflammatory for many diseases, including
ulcerative colitis. It is not known how EHH influences the response to I3C.
In the first study, we used the dextran sulfate sodium (DSS)-induced colitis mouse
model to study the role of Helicobacter muridarum bacteria with and without I3C
treatment. In this study, we focused on two main approaches; first, the pathology outcomes
after the bacterial infection and I3C treatment during the DSS course. The pathology
finding was studied by following the colitis symptoms like weight loss, diarrhea, blood in
the stool, and the histopathological examinations by a pathologist. Inflammation markers
were also measured in the plasma and in the colon to define the immunological profile for
those mice and compare the results between the I3C treated vs. untreated and infected vs.
uninfected groups. The second approach was to study the miRNAs in these groups.
miRNAs are a class of small non-coding RNAs that can negatively regulate genes involved
in the immune responses during physiologic and pathologic conditions.
Furthermore, many pieces of evidence show the participation of miRNAs in the
regulation of crucial immune functions, such as T-cell development, maturation, activation,
differentiation, and aging. Th17 cells, a subset of Th cells capable of producing IL-17 for
example, play a vital role in the formation of several autoimmune-mediated inflammatory
diseases, including IBD. Many studies demonstrate that several miRNAs act as positive
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regulators of Th17 differentiation, and others act as negative regulators [80]. On the other
hand, miRNAs also control T-regulatory cells (Treg); the cells that can suppress the activity
of effector T cells and maintain self-tolerance [81] miRNAs play crucial roles in the
regulation of both Treg cell development and function [80]. So as discussed, we studied
the role of the miRNAs in the Th17 and Treg cells and compared the immune and miRNAs
responses to H. muridarum infection with those seen in the DSS model and IBD patients.
The purpose of the second study was to study the role of Helicobacter hepaticus,
another enterohepatic Helicobacter species, in the DSS colitis model and the AOM/DSS
colon cancer model. H. hepaticus inhabits the lower gut, primarily the caecum. However,
some scientists think that it does not induce immune pathology in traditional mice [49].
However, infection of genetically vulnerable T and B cell-deficient 129SvEvRag−/− mice
results in colitis [50, 51]. Moreover, H. hepaticus exacerbates T cell transfer colitis in
C.B17 severe combined immunodeficient mice [82]. All these facts led us to believe that
host immune-regulatory responses are crucial, as H. hepaticus infection of lymphocytereplete mice with genetic- or pharmacological-induced deficiencies of the Interleukin10/Interleukin-10 receptor (IL-10/IL-10R) pathway additionally results in colitis and
typhlitis [83-85]. It is indicating that the IL-10 signal is vital to stop colitis in both humans
and mice. These facts collectively make us believe that H. hepaticus plays a protective role
during colitis and colon cancer diseases. We followed the first approach of the first study,
which is studying pathology and the immunology status for mice during the DSS colitis
course. We examined the effects of H. hepaticus during acute and chronic colitis and the
recovery period. Additionally, we studied the role of this bacteria in the AOM/DSS colon
cancer model.
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Finally, the last study's purpose was to examine the effect of different species of
Helicobacter on developing acute gut injury caused by DSS-treatment in male and female
mice with and without DSS treatment. The species used are known to infect humans: H.
cinaedi, H. fennelliae, H. hepaticus, and H.pullorum [55-58, 86]. These species are poorly
studied, and not much is known about their effects on human IBD. Intestinal pathology
arising from Helicobacter spp infection has only been documented for a few Helicobacter
species. H. hepaticus causes colitis with certain types of immune-deficient [49-52] and
germ-free mice [64]. H. muridarum bacteria have been studied on mono-associated
monogenic disorder mice (knockout gene or genes related to the immune system mice),
followed by the transfer of lymphocyte populations [60]; and another study with DSS [62].
Other than those, there are no in vivo studies examining the effects of enterohepatic
Helicobacter species on colon pathology. We examined variations generally illness activity
and histopathology between DSS and DSS + EHH-infected mice.
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CHAPTER 2

SIMILARITIES BETWEEN HELICOBACTER MURIDARUM-INDUCED
PATHOLOGY, DSS COLITIS, AND IBD AND RESPONSE OF H.
MURIDARUM-INFECTED ANIMALS TO INDOLE-3-CARBINOL1
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Nagarkatti , Mitzi Nagarkatti , Ioulia Chatzistamou , Marpe Bam , and Traci L. Testerman.
Submitted to World Journal of Gastroenterology
14

2.1 Abstract
Background: Enterohepatic Helicobacter (EHH) species are associated with an
increased risk of inflammatory bowel disease, but little is known about how these species
affect the immune system, whether animal models adequately mimic human disease, or
whether infection alters treatment response. Indole-3-carbinol (I3C) and other aryl
hydrocarbon receptor (AhR) agonists are known to modulate the immune system and
ameliorate various inflammatory and autoimmune diseases in animal models, including
colitis induced by dextran sulfate sodium (DSS).
Materials and Methods: We compared uninfected C57BL/6 mice, with and without
DSS treatment, to groups of mice infected with H. muridarum, again with or without DSS
treatment. Also, both infected and uninfected mice were treated with I3C. We determined
the immune response under each condition by measuring colonic and plasma cytokine
responses and identified mesenteric lymph node T cell subsets using flow cytometry and
qRT-PCR. We performed a microRNA array analysis on mesenteric lymph nodes and
confirmed some microRNA responses by qRT-PCR. Pathological responses were
evaluated by histological examination and evaluation of weight loss, diarrhea, and stool
blood.
Results: H. muridarum infection alone caused colonic inflammation and
upregulated proinflammatory, macrophage-associated cytokines in the colon, similar to
changes seen in DSS-treated mice. Further upregulation occurred upon treatment with
DSS. H. muridarum infection caused broad changes in mesenteric lymph node microRNA
expression, but colitis-associated microRNAs were regulated similarly in H. muridaruminfected and uninfected, DSS-treated mice. Many of the microRNAs altered by H.
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muridarum match those altered in inflammatory bowel disease (IBD) patients. Despite
causing colitis exacerbation, H. muridarum infection did not prevent disease amelioration
by I3C. I3C normalized both macrophage- and T cell-associated cytokines. Thus, H.
muridarum infection does not interfere with the AhR-mediated immune system
modulation.
Conclusions: H. muridarum infection of mice mimics many aspects of DSSinduced colitis and human IBD. I3C has similar anti-inflammatory effects on infected and
uninfected mice.
2.2 Introduction
Inflammatory bowel disease (IBD) is an umbrella term for chronic diseases,
including ulcerative colitis (UC) and Crohn’s disease (CD). In the past decade,
inflammatory bowel disease has emerged as a public health challenge and a global disease
with increasing incidence in newly industrialized and industrialized countries worldwide,
especially in North America and Europe [87]. In 2015, 3.1 million adults in the United
States were living with IBD [88], with direct and indirect costs estimated to be between
$14.6 and $31.6 billion in 2014 alone, the most recent year for which data are available
[89]. The pathogenesis of IBD is complex and influenced by genetic susceptibility,
dysregulation of the innate and adaptive immune systems, environmental factors, and
intestinal dysbiosis; however, a crucial feature of UC is the imbalance between T
regulatory (Treg) cells and T helper 17 (Th17) cells [90].
The best-known member of the Helicobacter genus is H. pylori, which colonizes
the stomach, causing gastritis, gastric cancer, and a range of extragastric diseases [91].
Enterohepatic Helicobacter (EHH) species colonize the colon and sometimes the biliary
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tree. Some of these poorly studied organisms occasionally cause intestinal diseases or even
cancer in species ranging from rodents to primates [92-94]. Several studies suggest that
EHH species contribute to IBD in humans [95-97]. The prevalence of EHH species in
human populations is not known, but one study found a 9% infection in healthy control
patients [97]. H. hepaticus is widely known for its ability to induce colitis or cancer in mice
with specific immunologic abnormalities [93], but does not cause colitis in wild-type mice
[65] and unpublished data). Helicobacter muridarum is an enterohepatic Helicobacter
(EHH) species that was initially described as a member of the normal flora of conventional
rodents [98]. Subsequent studies, however, showed that H. muridarum could induce colitis
and gastritis in mice, suggesting a potential pathogenic role for the bacterium [60, 61, 99].
Animal models of EHH-mediated colonic disease are needed and should be validated by
comparison with biomarkers of human IBD.
Dextran sodium sulfate (DSS)-induced colitis is the most widely used mouse colitis
model for studying both acute and chronic inflammation. DSS is a water-soluble,
negatively charged, sulfated polysaccharide with a highly variable molecular weight. DSSinduced murine colitis, which most closely resembles human UC, employs DSS at a
molecular weight of ~40000 Da [100, 101]. The mechanism by which DSS induces
intestinal inflammation is most likely cellular uptake via complexation with mediumchain-length fatty acids leading to cell cycle arrest, apoptosis, and disruption of tight
junctions [102-104]. This epithelial damage allows the dissemination of proinflammatory
intestinal contents. In conjunction with colonic damage, DSS induces a range of
proinflammatory cytokines and a Th1/Th17 response [101, 105].
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Over-the-counter dietary supplements are increasingly popular for disease
prevention or treatment, and the mechanisms of phytochemicals are being explored.
Several natural products act via the aryl hydrocarbon receptor (AhR), which regulates
several signaling pathways relevant to intestinal health, including the balance between
Tregs and Th17 cells [72, 73]. AhR is needed for the survival of intraepithelial lymphocytes
(IEL) and also the organogenesis of lymphoid structures in the gastrointestinal tract [71].
Indole-3-carbinol (I3C), a dietary compound from cruciferous vegetables such as broccoli,
activates AhR, as does its acidic condensation product, 3,3’-diindolylmethane (DIM)
[106]. Both I3C and DIM have been investigated as treatments for a range of inflammatory
diseases and cancers, including colitis [107-109], but the effects of Helicobacter infection
on the response to I3C has not been studied. Since I3C and DIM are available for purchase
as dietary supplements, it is essential to determine whether EHH infection interferes with
their activity.
MicroRNAs (miRNAs) are being investigated as potential diagnostic and treatment
tools. MiRNAs are highly conserved, noncoding, single-stranded, small ribonucleic acid
molecules (17–27 nucleotides) that control gene expression post-transcriptionally. They
typically bind at the 3’ untranslated region (UTR) of the target gene mRNA leading to the
degradation of the target RNA or inhibition of the translation of the RNA [80, 110].
MiRNAs regulate genes involved in a wide range of cellular signaling pathways, including
the Immune response. Substantial scientific evidence underlines the functional roles and
potential value of these tiny ribonucleic acid molecules for regulating autoimmunity and
inflammation by affecting the differentiation, maturation, and functions of various immune
cells in diseases including colitis [80, 111]. This includes miRNA participation in the
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regulation of T-cell development, differentiation, maturation, and activation [80, 81]. Since
the Treg/Th17 balance is crucial to intestinal health [112], understanding how miRNA
expression is controlled by inflammatory and anti-inflammatory signals could lead to the
identification of miRNAs capable of rebalancing the immune response in the inflamed
colon.
This study aimed to examine the pathogenesis of H. muridarum in comparison with
DSS treatment, to determine whether I3C acts similarly in H. muridarum-infected and
uninfected mice, and to compare immune and miRNA responses to H. muridarum infection
with those seen in the DSS model and IBD patients. We used the standard mouse model of
DSS-induced colitis in C57BL/6 mice. Treatment responses were monitored in the colon,
mesenteric lymph nodes, and plasma.
2.3 Materials and methods
2.3.1 Animals
The research described in this manuscript (including the acquisition of mice and all
protocols for their use) was approved by the University of South Carolina Institutional
Animal Care and Use Committee before the commencement of studies. The University of
South Carolina is an AALAC accredited institution, and all animal care procedures
followed the NIH Guide for the Care and Use of Laboratory mice. Female C57BL/6 mice
(aged 8-10 weeks) were purchased from The Jackson Laboratory, Bar Harbor, Maine,
USA. Mice were housed in a specific pathogen-free facility in standard shoebox cages with
pine bedding and no more than five mice per cage and a controlled environment (12 h
daylight cycle, temperature 20-26°C) with food and water ad libitum. After one week of
acclimation on a regular chow diet, the mice were randomly divided, and assigned to either
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experimental group. The animal protocol was designed to minimize pain or discomfort to
the mice. Oral gavage was carried out with conscious mice using straight gavage needles
appropriate for the animal size (2mm ball tip). Animal welfare was assessed at least once
daily. Mice were euthanized by CO2 asphyxiation at the end of the experiment or if they
lost more than 20% of initial body weight. Groups of 5-7 mice per group were used in each
experiment. The experimental groups included control (Ctrl), H. muridarum (Hm), H.
muridarum plus DSS (Hm/DSS), H. muridarum plus DSS plus I3C (Hm/DSS/I3C), DSS,
and DSS plus I3C (DSS/I3C).
2.3.2 Bacterial strains, cultivation, and infection
H. muridarum strain ATCC4982 was purchased from the American Type Culture
Collection (ATCC). It was cultured in a humidified environment at 37°C with 10% CO2,
5% O2 in Ham’s F-12 medium containing 2% fetal scalf serum in tissue culture flasks. H.
muridarum bacteria were passaged every 2 to 3 days. After microscopically verifying
proper morphology and motility, the culture was centrifuged at 25°C at 4500 rpm for 20
minutes. The pellet was suspended in 0.9% sodium chloride to produce a suspension
containing approximately 28465 to 142072 ATP relative luminescence units (RLU) per
200 μl, as determined using the luminescent BacTiter-Glo ATP viability assay (Promega
Corp., Madison, Wisconsin, USA). Mice were inoculated by orogastric gavage (200µl)
every other day for a total of four inoculations. The viability of the remaining bacterial
suspension was reconfirmed using the luminescent BacTiter-Glo ATP assay.
Infection was confirmed by PCR of stool DNA using H. muridarum-specific
primers as follows. Fecal samples were collected and stored at -80 C until analysis. Fecal
DNA was isolated using the EZNA stool DNA kit (Omega Bio-tek, Inc., Norcross Georgia,
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USA) according to the manufacturer’s recommendations. Fecal PCR was performed using
Helicobacter

muridarum

16S

rRNA

gene-specific

ATGGGTAAGAAAAAAAAAGATTGCAA-3’,

and

primers
H.m.

(H.m.

p30f,

p30r,

5’5’-

CTATTTCATATCCGCTCTTGAGAATC-3’), which amplify an ~800 bp conserved
region of the 16S rRNA, as previously described [113].
2.3.3 Induction of colitis with dextran sulfate sodium (DSS)
DSS (MW ~40000, Chem-Impex International, Inc, Wood Dale, Illinois, USA) at
a concentration of 1-3% was provided in drinking water for 10-13 days. The volume of
DSS taken, animal weight, diarrhea score, and stool blood scores were recorded daily. The
disease activity index (DAI) was calculated from weight, diarrhea, and stool blood scores,
as previously described [114, 115]. Stool blood was detected using a colorimetric fecal
occult blood test (Helena Laboratories, ColoScreen catalog #5083). Briefly, we determined
the DAI using the following variables: stool blood (0, negative; 1, weakly positive; 2,
strongly positive; 3, rusty-colored stool and 4, gross bleeding), changes in weight (0, <1%;
1, 1−5%; 2, 6−10%; 3, 11−15%, and 4, >15%), and stool consistency (0-1, normal; 2-3,
loose stools; and 4, diarrhea).
2.3.4 Indole-3-carbinol (I3C) preparation and dosage
For treatment groups, I3C purchased from Chem-Impex International, Inc. was
suspended in DMSO before dilution in corn oil. I3C was administered orogastrically at a
dose of 40 mg/kg in a total volume of 100 ul, as described previously [107]. Mice were
treated with either I3C or vehicle (2% DMSO in corn oil), beginning on the first day of the
DSS cycle.

21

2.3.5 Histopathological Colitis Score
Formalin-fixed colon tissue was embedded in paraffin and cut into five μm thick
sections. Next, the colon sections were stained using hematoxylin and eosin (H&E). Four
randomly chosen, non-overlapping fields of each stained section were analyzed and
assigned a colitis severity score by a pathologist using methods described previously [62,
115]. In short, the degree of colitis was scored based on the following parameters: the
extent of the injury (0, none; 1, mucosa; 2, mucosa and submucosa; and 3, transmural),
inflammation severity (0, none; 1, mild; 2, moderate; and 3, severe), and crypt damage (0,
none; 1, basal one-third damaged; 2, basal two-thirds damaged; 3, crypt loss and the
presence of surface epithelium; and 4, loss of the entire crypt and epithelium). Then the
degrees for each of these parameters above were multiplied by an extent score that
represented the percentage of each parameter that had a given feature as follows: 1, 0−25%;
2, 26−50%; 3, 51−75%; and 4, 76−100%. We defined the total score as the sum of the three
parameters. The bottom limit total colitis score was 0; the upper limit total.
2.3.6 Characterization of CD4+ T cells in the mesenteric lymph node (MLN) and spleen
For flow cytometry, the mesenteric lymph nodes (MLN) and spleens were pooled
from each group of mice and placed in ice-cold medium. These tissues were mechanically
disrupted, teased into single-cell suspensions, filtered through a cell strainer (70 μm), and
placed in complete medium (RPMI-1640 containing 10% of heat-inactivated fetal bovine
serum). The isolated cell suspension was stimulated with a cell stimulation cocktail
(eBioscience™) plus protein transport inhibitors (Invitrogen, catalog #00-4975) for 4-6
hours. Stimulated cells (1x10⁶) were incubated with anti-CD4 mAb and anti-CD25 mAb
for 15 min on ice (Biolegend, USA). For intracellular cytokine staining, the cell suspension
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was incubated with anti-IFNγ (Th1), IL-17 (Th17) after treating the cells with a
Fixation/permeabilization kit (BD Biosciences Catalog # 554714). For Treg identification,
we used the Foxp3/Transcription Factor Staining Buffer Set (eBioscience Invitrogen)
before adding anti- Foxp3. Staining and washing were carried out in complete medium on
ice. The stained cells were analyzed with a Beckman Coulter FC500 flow cytometer.
2.3.7 Enzyme-linked immunosorbent assays
Interleukin-17 (IL-17), Interleukin-6 (IL-6), Interleukin-10 (IL-10), Interleukin-4
(IL-4), interleukin-6 (IL-6), Interleukin-21 (IL-21), Interleukin-23 (IL-23), Interleukin1β (IL-1β), Transforming Growth factor-beta 1 (TGF-β1), Tumor Necrosis factor-alpha
(TNF-ɑ) and Interferon-gamma (INF-γ), in the plasma and/or in colonic tissue lysates were
quantified by ELISA kits (R&D Systems, Minneapolis, MN, USA) following the
manufacturer’s recommendations. Colon tissues were prepared for ELISA, as described
previously [114]. Briefly, the mouse colons were washed immediately with cold
phosphate-buffered saline and frozen at -70C° until use. The samples were homogenized
in 200 µl protein analysis buffer (10 mL of 1M tris-hydrochloric acid (pH=8.0), 6 mL of
5M sodium chloride, and 2 mL of Triton X-100 to 182 mL of sterilized distilled water)
[114]. In 2 ml microcentrifuge tubes with a 0.9-2.0 mm stainless steel bead blend, the
sampled were homogenized with a tissue homogenizer (MP FastPrep-24) at a speed of 0.4
m/s for 20 seconds. Samples were frozen and thawed and homogenized three times, then
centrifuged at 30,000 × g for 30 minutes at 4°C. The supernatant was collected, and the
pellet was re-suspended in phosphate buffer. Protein concentrations were determined using
a bicinchoninic acid assay (Bio-Rad). Samples were frozen until the ELISA assays were
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performed, and 0.5-1.0 mg/ml of protein was used for each run, depending on the
interleukin type.
2.3.8 Sample collection and RNA isolation
Mesenteric lymph nodes were collected from the groups on the day of the sacrifice
and immediately frozen at -70 C° before use. Mesenteric lymph nodes were ground with
mortar and pestle in liquid nitrogen. QIAzol Lysis Reagent (Qiagen, catalog #217004) was
added to the samples, and they were then homogenized by MP FastPrep-24 with 0.9-2.0
mm stainless steel beads (0.4 m/s for 10 seconds). Total RNA, including mRNA, miRNA
and other small RNA molecules, were isolated from all the mesenteric lymph node with
the miRNeasy Kit (Qiagen, Germany), following the manufacturer's procedure. The
concentration and purity of the isolated RNA were determined using a Beckman Coulter
DU800 UV/visible spectrophotometer. RNA quality was assessed by measuring the
absorbance (A260/A280, A260/A230) of isolated samples and by agarose gel
electrophoresis.
2.3.9 MicroRNA array analysis
The microarray was performed at the Unversity of South Carolina School of
Medicine following the protocol described by Bam et al.[116, 117]. Briefly, total RNA
isolated as described above, was hybridized to an Affymetrix miRNA-v3 gene chip
(Affymetrix, Sunnyvale, CA, USA) as directed by the manufacturer. Raw data was
processed in the Transcriptome Analysis Console (TAC, Affymetrix). The heat map was
generated in Genesis [118]. The data from TAC were used to calculate the linear foldchange of the expression of miRNAs to compare the miRNA expression differences among
treatment groups. A linear fold-change of at least ±1.5 was used as a cutoff value for the
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inclusion of a miRNA for further analysis. Moreover, only the miRNAs which were
significant based on p-value (<0.05) calculated using the student’s t-test, were included in
the analysis.
2.3.10 MicroRNA-target gene prediction
Ingenuity Pathway Analysis (IPA, Qiagen, Redwood City, CA, USA) was used to
predict the targets of the differentially expressed miRNAs. Networks relevant to regulatory
T cells were generated to identify relevant miRNA species for testing. Other databases
(TargetScan (http://www.targetscan.org/vert_72/), miRWalk (http://mirwalk.umm.uniheidelberg.de/)) were also used to identify genes targeted by specific miRNAs.
2.3.11 Quantitative real-time PCR analysis of miRNA and gene expression
Total RNA from MLN was isolated and purified with the miRNeasy Kit (Qiagen,
Valencia, CA), following the manufacturer's procedure. The miScript II RT cDNA
synthesis kit (Qiagen, Germany) was used according to the manufacturer's specifications
to reverse-transcribed cDNA by taking 1 μg each of total RNA in a 20 μl total volume. The
qRT-PCR reactions were carried out using miScript Primer Assays or miScript Precursors
(Qiagen, Germany) according to manufacturer instructions. U6, SnorD96, Snor68,
Snor234, and Snor202 were evaluated for stability among groups, and SnorD96 was chosen
for normalization. SnorD96 has also been used by others [119, 120]. Primers were
purchased from Qiagen, Maryland.
For mRNA expression analysis, cDNA was made from total RNA as described. A
two-step amplification qRT-PCR was carried out using SsoAdvanced™ SYBR® green
supermix from Bio-Rad (Hercules, CA, USA) with the mouse primers shown in Table 2.1
The real-time PCR conditions were as follows: initial step at 95°C for 10 sec and cycles
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(n = 40) consisted of 30 seconds at 95°C, followed by 30 seconds annealing/extension at
60°C and a final extension for 30 seconds at 72°C. Data are normalized to the expression
of the reference gene encoding β-actin. Primers were purchased from Integrated
Technologies and Invitrogen. Melting temperatures ranged from 56.0 to 64.5 °C. Primer
efficiency was measured for each primer set. All reactions were performed in triplicate.
The qPCR experiments were carried out on a CFX96 Touch Real-Time PCR Detection
System (Bio-Rad, Hercules, CA, USA). Fold changes were calculated using the 2−ΔΔCT
(Livak) method.
2.3.12 Statistical analysis
The significance of differences between groups at single time points was
determined using the Mann-Whitney U-test using GraphPad Prism software (Version 8.2).
P values less than 0.05 were considered significant. Colitis symptom time course data were
analyzed using a repeated measure analysis with 13 measures taken per animal (day1 to
day 13). Randomly assigned to six groups: control (Ctrl), H. muridarum (Hm), H.
muridarum plus DSS (Hm/DSS), H. muridarum plus DSS plus I3C (Hm/DSS/I3C), DSS,
and DSS plus I3C (DSS/I3C), and three experiments. Descriptive statistics were computed
on the variables. For categorical variables, the univariate constructions will be included
frequency distributions. For continuous variables, statistics included the measure of central
tendency (mean and median) and measure of spread (standard deviation and range). Group
will do the descriptive statistics for the main variables. In the analysis, expected mean
squares were calculated, and the appropriate combination used for hypothesis tests with
specific functions of the repeated measures. General linear model analyses in SAS
(MIXED procedure) were used to examine the effects of 1) day, 2) group, and 3) day by
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group interaction. Post-hoc comparisons for the appropriate effects were examined.
Besides, parameter estimates of the effects of the covariate (experiment), and the
appropriate structure for the repeated observations were estimated. Adjusted TukeyKramer multiple comparisons were used for significant effects. The level of statistical
significance was set at 0.05.
2.4 Results
2.4.1 Exacerbation of colitis by H. muridarum is counteracted by I3C treatment
Wild-type C57BL/6 mice were infected with live H. muridarum (Hm) and treated
with 1-3% DSS. 3% DSS produced such severe disease in H. muridarum-infected, DSS
(Hm/DSS) treated mice that euthanasia was sometimes required, leading us to reduce the
DSS concentration in subsequent experiments. Figure 2.1 shows the average values of three
independent experiments. Statistical analysis results are shown in Tables 2.2 and 2.S1. Hm
alone did not cause appreciable symptoms. In the presence of DSS, Hm decreased diarrhea
scores, but increased fecal occult blood and weight loss. I3C was as effective in
ameliorating colitis symptoms in Hm mice as it was in uninfected, DSS-treated mice. While
Hm alone did not cause clinical symptoms, it resulted in a shortened colon and significant
inflammation (Figure 2.1B). DSS treatment of Hm mice caused considerably worse
pathology than DSS alone. In some cases, pathology caused by Hm alone is comparable to
that caused by DSS treatment, yet damage to the mucosa was not reflected in symptom
scores in these mice.
2.4.1 H. muridarum infection increases the Th17 response to DSS.
Mesenteric lymph node (MLN) transcript analysis by qRT-PCR demonstrated that
while Hm alone did not alter RORC or Foxp3 expression, the addition of DSS treatment
increased Rorc and IL17 expression substantially more than DSS alone, indicating a Th17
27

response. I3C decreased Rorc and increased Foxp3 expression, consistent with a switch
from Th17 to Treg. These results were mirrored by the decrease in IL17 and an increase in
IL10 expression, consistent with other studies of the response to I3C colitis and other
disease models [121-123]. Although Foxp3 was less strongly induced by I3C in H.
muridarum-infected mice, IL10 expression was similar to that of uninfected mice treated
with I3C. These results were corroborated by flow cytometry (Figure 2.6).
2.4.2 Production of cytokines in colon tissue and plasma
We next measured cytokine concentrations in colon homogenates and plasma to
assess local and systemic immune responses. Infection with Hm alone increased all proinflammatory cytokines tested except IL-17 and IL-23 compared with control mice (Figure
2.3). Cytokine levels in H. muridarum-infected mice were similar to those in uninfected,
DSS-treated mice. Cytokine levels trended higher in Hm/DSS mice compared to DSS mice,
but this was only significant in the case of TNFα. I3C treatment reduced secretion of all
pro-inflammatory cytokines in DSS-treated mice with our without H. muridarum infection.
Levels of the anti-inflammatory cytokines IL-10 and TGFβ were only significantly
altered by I3C, though TGFβ levels trended lower in DSS-treated mice (Figure 2.3). IL-4
and IL-22 were not significantly altered under any condition (Figure 2.7).
Plasma cytokines mirrored symptom scores better than colon cytokines. Hm alone
did not alter any of the cytokine concentrations. IL-17 and IL-6 cytokine concentrations
were comparable between the DSS and Hm/DSS groups (Figure 2.4). I3C treatment
reduced both to control levels. IL-10 and IL-4 were elevated by I3C in DSS and/or Hm/DSS
mice (Figure 2.5). TGFβ was reduced only in H. muridarum-infected mice and did not
respond to I3C treatment. As additional markers of inflammation, we tested serum amyloid
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A and myeloperoxidase in plasma. The neutrophil marker myeloperoxidase was sharply
increased by Hm infection, even in the absence of DSS treatment (Figure 2.4). Both serum
amyloid A and myeloperoxidase were elevated by Hm/DSS.
2.4.3 Effects of H. muridarum, DSS, and I3C on miRNA expression
Since miRNAs contribute to immune cell differentiation and may be useful as
disease biomarkers, we sought to determine which miRNAs were regulated by H.
muridarum and/or I3C and whether the miRNA response to H. muridarum reflects miRNA
changes seen in human IBD. To accomplish this, we performed miRNA analysis on total
RNA isolated from the mesenteric lymph nodes of all groups from one of the experiments.
A heat map of miRNA expression intensity shows dramatic differences between the control
and treated groups (Figure 2.5A).
We sought to determine whether I3C-regulated miRNAs are associated with
regulation of the significant Treg and Th17 transcriptional regulators, Foxp3, and Rorc. To
this end, we used in silico analysis of predicted miRNA targets and pathways as well as
online databases to search for miRNAs induced by I3C in Hm/DSS mice that could target
Foxp3 and Rorc. Among these potential miRNAs, we identified three candidates that had
acceptable alignment scores and were highly predicted to target Foxp3 or Rorc. These
miRNAs included miR-let7a-5p and miR-29a-3p, which target Rorc, and miR-874-5p and
miR-6906-5p, which target Foxp3. It should be noted that other members of the let-7 family
also target Rorc, and some were similarly regulated by I3C in H. muridarum-infected mice.
We performed qRT-PCR on cDNA samples reverse transcribed from total MLN RNA. The
differences between control and Hm/DSS were significant in all cases, as were differences
between Hm/DSS and Hm/DSS/I3C (Figure 2.5B). The miRNAs mir-15b and miR-16
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support Treg development by targeting a suppressor of Treg development and miR-15b/16
previously have been shown to be induced by DIM [124, 125]. We also found these
miRNAs to be increased by I3C in H. muridarum-infected, DSS-treated mice (Figure 2.8).
We next sought to determine how the response to H. muridarum compares to the
response to DSS and to human IBD. The first Venn diagram shown in figure 2.5C
highlights miRNAs that changed more than 2-fold in the colitis groups compared with the
control group. The Hm group has 679 miRNAs up- or down-regulated compared with the
control, vs. 666 miRNAs in the DSS group, and 722 miRNAs in the Hm/DSS group.
Interestingly, the majority (n=574) of the miRNA changes are shared between the Hm
group and the DSS group, and most of these (n=543) are also shared with the Hm/DSS
group as well. This demonstrates that the miRNA response to H. muridarum infection is
very similar to the response induced by DSS treatment. Additionally, miRNAs common
between the Hm group and the DSS group were almost all regulated in the same direction.
All miRNA data are found in Tables 2.3, 2.4.
To determine whether there were specific miRNA responses to I3C, we first
compared infected and uninfected groups with their respective I3C-treated groups (Figure
2.5C, center). This resulted in an unexpected overlap of 87 miRNAs, or 23.5%. An
alternative method for Identifying I3C effects is to compare Hm/DSS/I3C vs. control with
DSS/I3C vs. control (Figure 2.2C, right). These miRNA populations overlap heavily
(73.1%). Most of the 87 previously identified miRNAs (56/87) are found in the overlap
group. Since there is also a heavy overlap between the putative I3C-regulated miRNAs and
DSS-regulated miRNAs (529/666), it is not clear whether any of the miRNAs are strictly

30

responsive to I3C; however, the overlap is consistent with the hypothesis that I3C
normalizes miRNAs involved in colitis.
Examination of specific miRNAs provides a clearer demonstration of the effects of
H. muridarum, DSS, and I3C and an explanation for the differential regulation of miRNAs
by I3C in infected vs. uninfected mice. We examined a list of 138 miRNAs that are altered
in human IBD (Crohn’s disease and/or ulcerative colitis) [126-130]. The majority (n=90,
65%) were altered in at least one H. muridarum-infected group, and most of those were
altered in all colitis groups. From this list of 138, we found 39 miRNAs that were reported
to be altered in IBD by more than one study. All but three of those were up- or downregulated by at least two-fold by Hm or Hm/DSS, although expression levels of mir-1425p, mir-215-5p, mir-375-3p, and mir-7a-5p were weak. Table 2.3 shows raw expression
data and fold changes for the selected miRNAs. Expression changes were most extreme in
Hm/DSS vs. control- up to 3,646-fold decreased (mir-16-5p). The expression changes were
negative; however, there was not a global decrease in miRNA expression in any treated
groups vs. controls. Thus, the decreases are specific to certain miRNAs. All but six human
IBD-associated miRNAs were among the 543 miRNAs common among the colitis groups
(Figure 2.2C). About half of the human IBD-associated miRNAs are also altered in mouse
models of colitis [131-135], suggesting that a core set of miRNAs are relevant to colitis in
both humans and mice.
2.5 Discussion
Several models of inflammation and inflammatory bowel disease suggest that
bacteria are necessary, but insufficient triggers of IBD [136], and several studies have
reported that EHH species modulate IBD. As an example, H. macacae has been connected
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with chronic idiopathic colitis in young rhesus macaques, and a study of children with CD
reported PCR evidence for Helicobacter infection in 59% of patients vs. 9% of healthy
controls [97, 137]. Similarly, Laharie et al. found that H. pullorum or H. canadensis
infection was considerably related to CD in adults [96]. Finally, H. canis, another EHH
species, has been detected in duodenal ulcerations associated with CD [138]. Therefore,
certain Helicobacter species are almost certainly involved in IBD pathogenesis; however,
the exact mechanism of EHH involvement remains to be explored.
Th17 cells play a crucial role in colitis development in both humans and mouse
models [35, 139]. H. pylori are known to induce a Th17 response in the gastric mucosa
[37, 39, 140], yet H. pylori infection is associated with a decreased risk of IBD [40]. H.
pylori only colonize the gastric mucosa, meaning that any effects of H. pylori on the colon
are likely due to the systemic effects of infection. Furthermore, EHH species lack the major
H. pylori virulence factors cagA and vacA. Thus, one cannot assume that mucosal or
immune effects of H. pylori infection will match those caused by EHH species. It is,
therefore, necessary to use infection with EHH species to investigate potential mechanisms
of EHH-mediated contributions to IBD.
The present study extends existing knowledge on H. muridarum pathogenesis. H.
muridarum infection has been previously shown to induce colitis in C57BL/6 mice treated
with DSS and in monoassociated severe combined immunodeficiency (SCID) mice
following the transfer of specific T cell populations [60, 62, 141]. The increased weight
loss and stool blood are seen in Hm/DSS mice suggest damage to the mucosal barrier,
possibly with increased exposure to other members of the gut microbiota. On the other
hand, diarrhea was actually lessened. This could indicate intact fluid absorption capacity
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H. muridarum infection alone caused localized inflammation, indicated by
histopathology and increased pro-inflammatory cytokine production in the colon. On the
other hand, there was minimal evidence of systemic inflammation in these mice, with
plasma cytokine levels remaining low. The cytokines induced by H. muridarum alone
(TNFα, IL-1β, IL-6, and IFNγ) are typical of those induced by DSS treatment [101] and
those that are elevated in human IBD patients. In humans with IBD, increases in mucosal
TNFα, IL-1β, IL-6, IL-23, and IFNγ are due to lamina propria monocytes or macrophages
[142-144]. IFNγ is also produced by Th1 cells or potentially a new intraepithelial
lymphocyte subtype, IL-17+ IFNγ+ T cells [145]. Regardless of cell source, IFNγ plays an
important role in IBD pathology in humans and mice [146, 147]. Thus, the effects of H.
muridarum in our mouse model will likely be relevant to humans infected with
enterohepatic species. In general, H. muridarum infection more strongly influenced the
production of monocyte/dendritic cell-associated cytokines (TNFα, IL-1β, IL-6, IL-23)
compared to T cell-associated cytokines (IFNγ, IL-4, IL-10, IL-17, IL-21, IL-22).
Cytokines secreted by monocytes or dendritic cells can drive T cell differentiation.
TGFβ and IL-6 drive several differentiation pathways depending upon which other
cytokines are present [148]. The combination TGFβ, IL-6, and IL-23 efficiently induce
Th17 differentiation [149]. In spite of local cytokine responses suggestive of a Th17promoting milieu, we did not find evidence of a substantial T cell shift in mice infected
with H. muridarum alone. DSS treatment was required for enhanced expression of Rorc
and IL17 in lymph nodes or increased plasma IL-17. These data suggest that local effects
of H. muridarum are conducive to, but not sufficient for Th17 polarization. This is
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consistent with a “two-hit” hypothesis, although in this case, the two hits are H. muridarum
and an irritant rather than host genetics and the microbiome.
The use of alternative medicine to treat inflammatory disorders is appealing to
many patients. Numerous studies demonstrate that dietary indoles possess anti-cancer
properties such as anti-oxidant activity, regulation of cell cycle and apoptosis, and control
of endocrine metabolism [70, 150-154]. DIM is sold over the counter as BioResponse
DIM® with claims that it promotes breast health, prostate health, and weight management.
Before such products can be confidently recommended, their mechanisms of action must
be uncovered. In the case of IBD, it is prudent to investigate the effect of gut microbiota
on response to treatment.
Several natural compounds, including I3C, are AhR ligands [155]. AhR is now
known to govern the differentiation and function of both T cells and macrophages [156]
[71, 157]. Several studies have shown that AhR plays a vital role in the regulation of
immune responses, specifically promoting the generation of Tregs while suppressing Th17
cells [158, 159]. Consistent with other reports from various disease models, we found that
I3C increases the Treg population and decreases the Th17 population [122, 160, 161]. We
found no evidence that H. muridarum alters the I3C response in any way, indicating that
AhR ligands will be equally effective in patients who may be infected with EHH species.
There is increasing interest in the use of miRNAs to diagnose and treat a wide
variety of diseases and cancers. We examined mesenteric lymph node miRNA expression
to determine whether miRNA signatures explained the effects of H. muridarum and I3C.
Many studies show that miRNAs participate in the regulation of crucial lymphocyte
functions such as lymphocyte development, maturation, activation, and differentiation. [80,
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158, 162, 163]. When considering the roles of miRNAs in Treg and Th17 function, it is
necessary to distinguish between miRNAs involved in T cell differentiation and miRNAs
involved in the function. For example, miRNAs binding to the Treg transcriptional
regulator gene Foxp3 prevent differentiation of Tregs and must be downregulated to allow
Treg differentiation. Some miRNAs promote Foxp3 expression by downregulating the
expression of other genes, while others are induced by Foxp3 and influence Treg function.
Still, other miRNAs act in an autocrine manner, being both induced by Foxp3 and inducing
Foxp3 expression [164]. Therefore, miRNA expression patterns can differ between naïve
and mature T cells and between highly active and anergic T cells. A further complication
of miRNA interpretation is that the same miRNA can have different effects depending on
the cell type in which it is expressed. For example, miR-155 reportedly induces both Treg
and Th17 cell differentiation [165], making it impossible to predict whether increased miR155 in the lymph node or even within the T cell population, favors a Treg or Th17
phenotype. Relative concentrations of miRNAs within each cell most likely dictate the cell
phenotype.
These nuances explain the often disparate and contradictory results published in the
literature. For example, Iborra et al. sought to compare serum and mucosal miRNAs
profiles in human ulcerative colitis and Crohn’s disease [128]. They found little overlap
between serum and tissue miRNAs and many differences between their results and those
published by others. Each miRNA has hundreds or thousands of targets [166], and each
gene is likely controlled by dozens of miRNAs. In the context of IBD and colon cancer,
miR-15b/16 is reported to regulate Tregs, macrophages, TP53, aquaporin 8, and the
adenosine A2a receptor [124, 167-170]. Surprisingly, miR-16 has even been suggested as
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a stable reference miRNA [171]. The multiple targets of miR-15b/16 may then explain why
treatment of mice with miR-16 precursors ameliorates colitis, yet elevated miR-16 in
human blood samples is associated with more severe IBD [167, 172, 173].
The above caveats explain why the direction of miRNA regulation in our study was
not always intuitive. For example, if a miRNA is highly expressed in control mice and
drops following colitis induction, one would expect to be increased following I3C
treatment. This was not always the case. I3C increased the number of cells found in MLN,
and likely the ratios of cell types. The fact that I3C altered roughly the same subset of
miRNAs as DSS or H. muridarum is consistent with its known anti-inflammatory effects
but does not shed light on the mechanism of I3C activity. Rather, the results are consistent
with the hypothesis that miRNA changes due to I3C result from, rather than the cause,
immune response normalization.
The same principle applies when comparing results among human IBD studies or
comparing human and animal results. The human studies used either peripheral blood or
colon biopsies as a source of miRNAs, whereas we used mesenteric lymph nodes [128130]. Lymph nodes differ in cellular composition compared to peripheral blood [174], and
since the cell subsets change following H. muridarum infection or DSS treatment, the ratios
of T cells to dendritic or other cell populations may change as well. Because colitisassociated miRNAs are likely expressed in multiple cell types, the meaning of a miRNA
increase, or decrease cannot be deciphered without knowing whether they rise or fall in
each cell subtype. Nonetheless, when examining a particular sample type (e.g., plasma or
biopsy), it may be possible to obtain changes in consistent directions.
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In summary, our studies suggest that H. muridarum increases susceptibility to DSSinduced colitis by inducing macrophage-associated cytokines and creating a mucosal
milieu conducive to Th17 polarization. I3C ameliorates colitis regardless of infection, and
immune changes seen after I3C treatment are consistent with those published by others,
warranting further research on the use of I3C or similar AhR agonists for the treatment of
inflammatory bowel disease. The identities of miRNAs altered by H. muridarum and DSS
were similar to colitis studies in both mice and humans. Thus, H. muridarum infection of
mice is likely to be a useful model for studying the potential effects of EHH species on
susceptibility to IBD and other intestinal disorders.
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Table 2.1. The mouse forward and reverse primers for the genes of interest.

Gene

Forward primer

Reverse primer

ACTB

5′TCACCCACACTGTGCCCAT
CTACG-3′

5′CAGCGGAACCGCTCATTGC
CAATGG-3′

5′TCAGCGTGTCCAAACACTG
AG-3′
5′AGCAGTCCACTTCACCAA
GG -3′
5′CCGCTGAGAGGGCTTCAC3′
5′TGAATTCCCTGGGTGAGA
AGC3′
5′AGCCAGAGTCCTTCAGAG
AGAT-3′

5′CGCCAAGGGAGTAAAGACT
T-3′
5′GGATAACGCCAGAGGAGCT
G -3′
5′TGCAGGAGTAGGCCACATT
ACA-3′
5′-ATCACTCTTCACCTCCAC3′

(β-actin)
IL17A

Foxp3

Rorc

IL10

IL6
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5′AAAAAGTGCCGCTACCCTG
A -3′

Table 2.2. Significance levels of colitis symptom score comparisons. Significant
values are printed in bold.
Treatment groups
Ctrl vs.

Hm vs.

Hm/DSS vs.

DSS vs.

%Weight

Stool blood

Diarrhea

Hm

0.2495

0.6142

0.0248

0.0659

Hm/DSS

<.0001

<.0001

<.0001

<.0001

Hm/DSS/I3C

0.9574

<.0001

<.0001

<.0001

DSS

0.0552

<.0001

<.0001

<.0001

DSS/I3C

0.1381

<.0001

<.0001

<.0001

DSS

0.9823

<.0001

<.0001

<.0001

Hm/DSS

<.0001

<.0001

<.0001

<.0001

DSS

<.0001

0.0007

0.0041

<.0001

Hm/DSS/I3C

<.0001

<.0001

<.0001

<.0001

DSS/I3C

0.9977

0.0026

<.0001

<.0001
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DAI

Table 2.3 Mouse homologs of human miRNAs commonly altered in inflammatory bowel
disease and/or ulcerative colitis patients: raw expression data.
miRNA
mmu-let-7a-5p
mmu-let-7b-5p
mmu-let-7d-5p
mmu-let-7e-5p
mmu-let-7g-5p
mmu-miR-103-3p
mmu-miR-106a-5p
mmu-mir-126a-3p
mmu-miR-127-3p
mmu-miR-140-3p
mmu-miR-142-5p
mmu-mir-143-3p
mmu-miR-146a-5p
mmu-miR-150-5p
mmu-miR-155-5p
mmu-miR-16-5p
mmu-miR-18a-5p
mmu-mir-192-5p
mmu-mir-194-5p
mmu-miR-195a-5p
mmu-miR-196b-5p
mmu-miR-199a-5p
mmu-mir-19b-3p
mmu-miR-20b-5p
mmu-mir-215-5p
mmu-mir-21a-5p
mmu-miR-223-3p
mmu-miR-24-2-5p
mmu-mir-26a-5p
mmu-miR-27a-3p
mmu-miR-29a-3p
mmu-miR-29c-3p
mmu-mir-30b-5p
mmu-miR-30e-5p
mmu-mir-375-3p
mmu-mir-422a
mmu-mir-441
mmu-mir-650
mmu-mir-7a-5p

CTRL

Hm

12.93 11.14
14.14 11.84
13.76 11.52
11.06 10.06
10.31
6.71
11.85 10.44
9.29
5.45
11.61
9.45
7.9
4.55
10.2
9.92
2.9
0.99
11.9
9.5
10.34
7.84
13.4
11.1
9.86
8.15
13.18 10.38
7.32
1.37
7.02
1.36
8.36
5.29
10.59
8.03
3.11
0.94
9.5
4.56
9.43
6.13
9.03
4.87
2.81
1.21
7.7
0.69
5.45
1.57
12.74 10.84
14.3 11.31
9.96
5.94
10.97
8.84
5.38
0.87
9.7
7.59
7.8
1.13
1.38
2.51
not found
not found
not found
3.87
1.15
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Hm/ Hm/
DSS DSS/
DSS/I3C
DSS
I3C
5.72
9.11 10.71 10.59
7.97
10.45 11.21 10.89
8.09
10.44
11.1 10.86
1.7
8.39
9.6
9.23
1.37
2.01
7.52
6.16
6.42
10.09 10.88 10.02
1.15
2.03
5.51
2.78
1.02
6.73 10.14
7.98
0.95
2.8
2.43
1.91
1.83
7.91
9.62
8.3
1.35
0.99
1.16
1.01
3.44
9.3
10.4
9.54
1.24
3.54
7.72
7.84
4.14
8.96
10.4
9.76
1.54
3.58
7.65
5.31
1.35
9.1
10.8
9.11
0.84
1.37
1.41
1.74
1.44
1.83
1.57
1.18
1.08
1.28
4.52
1.11
1.91
5.03
8.22
7.39
0.94
1.08
1.05
0.83
1.77
2.01
7.72
1.77
1.18
5.87
7.97
5.61
1.76
2.29
5.85
1.96
1.07
0.95
0.81
0.99
1.35
1.11
1.6
2.05
1.01
0.99
1.84
0.87
1.78
9.51
10.8 10.12
3.52
10.4 11.54 10.33
1.35
1.57
8.22
5.2
2.38
7.73
9.45
7.38
1.23
1.28
2.05
1.8
1.66
3.82
8.17
7.49
1.64
1.64
3.46
1.32
0.85
1.06
1.07
1.2

1.15

1.15

1.15

0.83

Table 2.4 Mouse homologs of human miRNAs commonly altered in inflammatory bowel
disease and/or ulcerative colitis patients: Fold changes data.
miRNA

Hm
vs.
Ctrl

Hm/
DSS vs.
Ctrl

Hm/DSS/ DSS
I3C vs.
vs.
Ctrl
Ctrl

DSS/
I3C vs.
Ctrl

DSS/
I3C
vs.
DSS

-5.07
-9.56
-7.42
-3.54
-17.81
-3.57

Hm/
DSS/I
3C vs.
Hm/D
SS
10.5
5.56
5.08
103.31
1.55
12.7

mmu-let-7a-5p
mmu-let-7b-5p
mmu-let-7d-5p
mmu-let-7e-5p
mmu-let-7g-5p
mmu-miR103-3p
mmu-miR106a-5p
mmu-mir126a-3p
mmu-miR127-3p
mmu-miR140-3p
mmu-miR142-5p
mmu-mir-1433p
mmu-miR146a-5p
mmu-miR150-5p
mmu-miR155-5p
mmu-miR-165p
mmu-miR18a-5p
mmu-mir-1925p
mmu-mir-1945p
mmu-miR195a-5p
mmu-miR196b-5p

-3.45
-4.92
-4.71
-2
-12.19
-2.66

-147.58
-72.01
-50.67
-654.64
-491.93
-43.07

-14.06
-12.96
-9.97
-6.34
-317.1
-3.39

-4.65
-7.62
-6.29
-2.74
-6.92
-1.96

-14.34

-282.96

-153.91

-13.78

-91.54

1.84

-6.64

-4.46

-1538.43

-29.41

-2.76

-12.33

52.31

-4.47

-10.18

-123.98

-34.2

-44.34

-63.55

3.63

-1.43

-1.21

-329.16

-4.87

-1.49

-3.73

67.62

-2.51

-3.78

-2.93

-3.78

-3.34

-3.72

-1.29

-1.11

-5.28

-352.53

-6.07

-2.84

-5.15

58.09

-1.81

-5.65

-550.48

-111.6

-6.13

-22.7

4.93

-3.7

-4.92

-614.48

-21.78

-8.01

-12.51

28.22

-1.56

-3.27

-320.03

-77.72

-4.61

-23.48

4.12

-5.09

-7

-3646.25

-16.92

-5.22

-16.9

215.51 -3.23

-61.84

-89.41

-61.84

-60.29

-47.91

1.45

1.26

-50.57

-47.92

-36.57

-43.75

-57.45

1.31

-1.31

-8.38

-155.43

-135.47

-14.28

-152.36

1.15

-5.89

-409.38

-47.19

-5.17

-9.14

8.68

10.67
-1.77

-4.49

-4.49

-4.09

-4.19

-4.86

1.1

-1.16
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-1.09
-1.25
-1.18
-1.29
-2.58
-1.82

mmu-miR199a-5p
mmu-mir-19b3p
mmu-miR20b-5p
mmu-mir-2155p
mmu-mir-21a5p
mmu-miR223-3p
mmu-miR-242-5p
mmu-mir-26a5p
mmu-miR27a-3p
mmu-miR29a-3p
mmu-miR29c-3p
mmu-mir-30b5p
mmu-miR30e-5p
mmu-mir-3753p
mmu-mir-422a
mmu-mir-441
mmu-mir-650
mmu-mir-7a5p

-2.03

-101.88

-21.49

-3.71

-78.21

4.74

-9.84

-303.99

-11.79

-2.74

-14.07

25.78

21.08
-5.14

-17.77

-154.33

-106.75

-9.05

-133.96

1.45

-14.8

-3.04

-3.34

-3.64

-4.01

-3.55

-1.09

1.13

-81.74
129.28
-14.69 -21.58

-96.84

-68.79

-50.38

-1.18

1.37

-21.99

-12.14

-23.85

-1.02

-1.96

-56.17

-101.73

-64.83

-72.38

-48.35

1.57

1.5

-7.97

-1760.92

-14.89

-6.77

-15.64

118.29 -2.31

-16.28

-390.62

-337.26

-3.34

-27.11

1.16

-8.12

-4.37

-386.19

-9.45

-2.86

-12.06

40.85

-4.21

-22.8

-17.81

-17.22

-10.08

-12.01

1.03

-1.19

-4.3

-263.54

-58.61

-2.89

-4.62

4.5

-1.6

-71.46

-14.68

-89.04

1

-4.42

-1.25

-1.24

-1.13

1.15

1.1

-6.61

-6.6

-8.25

1

-1.25

-71.46
101.76
2.2
-1.44
not found
not found
not found
-6.6
-6.61
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Table 2.5 Statistical analysis parameters.

group

N
Obs

Varia
ble

Mini
mum

Maxim
um

control

221

DAI
Diar
SBS
WT

dai
diarrhea
score
stool blood
score
weight 1

176 0.61
186 0.22
196 0.01
150 100.4
0

0.70
0.41
0.10
2.30

0.00
0.00
0.00
93.30

2.00
1.00
1.00
107.81

DSS

221

DAI
Diar
SBS
WT

dai
diarrhea
score
stool blood
score
weight 1

151 4.17
156 2.03
156 1.71
151 99.41

2.35
1.30
1.40
2.62

0.00
0.00
0.00
90.75

9.00
4.00
4.00
106.68

DSS13
C

221

DAI
Diar
SBS
WT

dai
diarrhea
score
stool blood
score
weight 1

151 3.08
156 1.46
156 1.23
151 99.58

2.07
1.14
1.28
3.76

0.00
0.00
0.00
82.75

8.00
4.00
4.00
115.52

H.m

221

DAI
Diar
SBS
WT

dai
diarrhea
score
stool blood
score
weight 1

168 1.11
173 0.49
178 0.19
138 99.60

0.95
0.61
0.39
2.17

0.00
0.00
0.00
92.87

3.00
2.00
1.00
105.21

DSS +
H.m

221

DAI
Diar
SBS
WT

dai
diarrhea
score
stool blood
score
weight 1

181 4.47
186 1.71
191 2.17
151 96.85

2.83
1.17
1.60
3.73

0.00
0.00
0.00
83.46

10.00
4.00
4.00
104.38

DSS +
H.m+1
3C

221

DAI
Diar
SBS
WT

dai
diarrhea
score
stool blood
score
weight 1

176 3.19
191 1.29
184 1.31
150 100.1
1

2.39
1.10
1.41
2.69

0.00
0.00
0.00
88.67

8.00
4.00
4.00
107.20

Label

N
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Std
Mean Dev

Figure 2.1. Symptom scores and histopathology. Panel A, colitis symptom scores.
Panel B, colon length and histopathology scores. Ctrl, untreated; Hm, H.
muridarum-infected; Hm/DSS, H. muridarum plus DSS; Hm/DSS/I3C, H.
muridarum plus DSS plus I3C; DSS, DSS treated; DSS/I3C, DSS plus I3C. *,
P<0.05; **, P≤ 0.01; ***, P ≤0.001.
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Figure 2.2. Expression of Th17 and Treg-associated genes in
mesenteric lymph nodes. Gene expression was determined from total
cDNA using qRT-PCR and values were normalized to the control
group. *, P<0.05; **, P≤ 0.01.
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Figure 2.3. Colon cytokine production. Protein levels were determined by ELISA
using colon homogenates. Data represent combined results from three experiments
with 16-21 mice per treatment group total. *, P<0.05; **, P≤ 0.01; ***, P ≤0.001.
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Figure 2.4. Plasma cytokine and inflammatory protein markers. Protein levels were
determined by ELISA using plasma collected at the time of euthanasia. *, p<0.05;
**, p≤ 0.01; ***, p ≤0.001.
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Figure 2.5. MiRNA expression analysis. A.) A heat map of expression intensities
for each group was generated using Genesis software with red representing high
expression and green representing low expression. B.) Expression of miRNA as
determined by qPCR. All values are normalized to expression in the control group.
C.) Venn diagrams generated using Venny 2.1 demonstrate miRNA expression
changes common to different treatment conditions. DSS, dextran sulfate sodium
treatment; Hm, H. muridarum treatment; I3C, indole-3-carbinol treatment. *,
P<0.05; **, P≤ 0.01.

48

Figure 2.6. Flow cytometry analysis of total mesenteric lymph node cells. Panel
A,Th17 cells were identified by IL-17 and CD4 staining. Panel B Treg cells were
identified by CD4, CD25, and Foxp3 staining. Panel C, MLN absolute number of
CD4+IL17+, and CD4+CD25+Foxp3+ cells. CTRL, untreated; Hm, H. muridaruminfected; Hm/DSS, H. muridarum plus DSS; Hm/DSS/I3C, H. muridarum plus DSS
plus I3C.
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Figure 2.7. Expression of miR-15b-5p and miR-16-5p was measured
by qRT-PCR and normalized to Hm/DSS/I3C.

Figure 2.8. Colon cytokine production. Protein levels were determined by
ELISA using colon homogenates.
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CHAPTER 3

HELICOBACTER HEPATICUS REDUCES COLITIS SEVERITY AND
COLONIC POLYP DEVELOPMENT IN MICE2

2

Rasha, Raheem Alkarkoushi, Yvonne Hui , Udai Singh , Prakash Nagarkatti , Mitzi
Nagarkatti , Ioulia Chatzistamou , and Traci L. Testerman. To be submitted to Helicobacter
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3.1 Abstract
Helicobacter hepaticus is known for its ability to induce colitis in certain colitisprone mouse strains; however, its impact on colitis and colon cancer development in wildtype mice had not been described. Wild-type C57/BL6J mice were infected with H.
hepaticus and then treated with dextran sulfate sodium (DSS) alone or in conjunction with
the carcinogen azoxymethane. Mice infected with H. hepaticus developed less severe
colitis that resolved more quickly than uninfected mice treated with DSS. Similarly, H.
hepaticus-infected mice developed fewer adenomas following treatment with
azoxymethane and DSS.

The anti-inflammatory cytokines IL-10 and TGF-β1 were

increased in H. hepaticus-infected, DSS treated mice compared with uninfected DSStreated mice while IL-21 and IFNγ were reduced. These results suggest that H. hepaticus
protects against colitis by modulating the immune response and is only a colonic pathogen
in mice with defective immune systems.
3.2 Introduction
Helicobacter hepaticus infection is widespread in mouse colonies worldwide [175]
and occurs in humans [176]. H. hepaticus inhabits the lower gut, primarily the caecum. It
was first associated with hepatitis and liver cancer in mice [177, 178]. Some scientists
report that it does not induce colon pathology in traditional mice, but infection of
genetically vulnerable T and B cell-deficient 129SvEvRag−/− mice results in
colitis/typhlitis [50, 51]. This indicates that colitis is not dependent upon adaptive
immunity, but T cell functions do contribute to colitis. For example, IL-10-deficient mice
readily develop colitis upon H. hepaticus infection [49, 85] Transfer of IL-10-producing
regulatory T helper (Treg) cells ameliorates H. hepaticus-induced colitis. In addition to T
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cells, phagocytic cells contribute to colitis pathology. Monocyte-derived macrophages
recruited to the lamina propria during colitis development secrete IL-23, which
subsequently drives the proliferation of inflammatory Th17 cells [84, 179, 180].
Additionally, infection with H. hepaticus induces colonic regulatory T cells that prevent
inflammation in an IL-10-dependent manner [83]. A polysaccharide produced by H.
hepaticus may be responsible for its anti-inflammatory properties, since it induces
macrophage production of IL-10 through a mechanism involving TLR2, MyD88, and
ERK1/2 [64, 181].
In humans, genetic mutations contribute to at least some cases of IBD. Mutations
in IL10 or IL10R lead to severe, early-onset forms of IBD [182-184], indicating that IL-10
signaling is vital for colitis prevention in both humans and mice. Mutations in genes for
other cytokines, cytokine receptors, or signaling proteins involved in the immune response
also contribute [185]. Such as IL-12, TNFα, and A particular IL-23 receptor mutation
actually decreases the risk of developing IBD [185, 186].
We studied the effects of H. hepaticus infection in wild-type C57BL/6 mice in the
presence and absence of dextran sodium sulfate (DSS ) treatment. DSS is a water-soluble,
negatively charged sulfated polysaccharide with a molecular weight ranging from 5 to 1400
kDa. DSS, with a molecular weight of ~40,000 induces severe murine colitis, which closely
resembles human UC [100]. DSS may cause colitis by damaging the epithelial monolayer
lining the large intestine, thus allowing the dissemination of proinflammatory intestinal
contents [187]. The mouse immune response also contributes to DSS-induced colitis, since
not all mouse strains are equally vulnerable [188].
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We found that H. hepaticus paradoxically causes colonic inflammation while also
reducing the severity of DSS-induced colitis. This may be explained by increased IL- 10
concentrations and an increased percentage of T-regs in the H. hepaticus-DSS infected
group compared to the DSS uninfected group.
3.3. Materials and methods
3.3.1 Mice
Male and female C57BL/6 mice (aged 8-10 weeks) were purchased from Jackson
Laboratory (Bar Harbor, Maine, USA). All mice were housed at the AAALAC-accredited
animal facility at the University of South Carolina, School of Medicine (Columbia, SC).
All procedures were performed according to NIH guidelines under protocols approved by
the Institutional Animal Care and Use Committee. Mice were housed in a controlled
environment (12 h daylight cycle) with food and water ad libitum. All the animal
experiments are done according to the ARRIVE guidelines for reporting experiments
involving mice [189, 190]. One week of acclimation on a regular chow diet, the mice were
randomly divided. After simple randomization using shuffled pieces of paper that indicated
treatment, mice were assigned to either experimental group.
3.3.2 Bacterial strains, cultivation, mice infection and infection confirmation
H. hepaticus strain 51448 was purchased from ATCC. H. hepaticus was cultured
in a humidified environment at 37°C with 5% CO2, in Ham’s F-12 medium containing 2%
fetal calf serum in tissue culture flasks. Bacteria were passaged into fresh medium every
2 to 3 days. After microscopically verifying proper morphology and motility, cultures were
centrifuged at 25°C at 4500 rpm for 20 minutes. The resulting pellet was suspended in 3
ml of sterile saline. Concentrated bacteria were administered orogastricaaly by gavage in a
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volume of 200µl. Viability of cultures was confirmed using the Bactiter-Glo Microbial cell
viability Assay (Promega Corp., Madison, WI, USA) Infection was repeated every other
day for a total of four doses.
Infection was confirmed by PCR analysis of stool DNA using
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genus-specific 16S primers (H276F, H676R), which amplify a ~700 bp conserved region
of the 16S rRNA, as previously described [191]. For some experiments and/or samples, we
ran PCR for using H. hepaticus -specific primers (p 25R, p 25F), which amplify a ~350400 bp conserved region of H. hepaticus, as previously described [192]. T Fecal DNA was
purified using the Omega EZNA stool DNA extraction kit (Omega Bio-tek Inc., Norcross
GA, USA) according to the manufacturer’s recommendations.
3.3.3 Induction of colitis with dextran sulfate sodium (DSS)
1-3 % of DSS (MW ~40000, Chem-Impex Int’l Inc, Wood Dale, IL, USA) was
given to previously infected mice with the bacteria in drinking water for 8-10 days. The
volume of DSS consumed, weight, diarrhea score, and blood scores were recorded daily.
The disease activity index was calculated as previously described [114, 115]. Briefly, a the
DAI was calculated using the following variables: stool blood (0, negative; 1, occult blood
positive; 2, Rusty; and 4, gross bleeding), changes in weight (0, <1%; 1, 1−5%; 2, 6−10%;
3, 11−15%, and 4, >15%), and stool consistency (0-1, normal; 2-3, loose stools; and 4,
diarrhea). Individual mice were identified by ear punches.

55

3.3.4 AOM/DSS model of Colitis-Associated Cancer
Mice were injected intraperitoneally with 10 mg/kg of azoxymethane (AOM ) (1
mg/ml in isotonic saline, diluted from 10 mg/ml stock solution in dH2O stored at -20°C) to
induce colon cancer [193, 194]. One week later, 2% DSS was administered via drinking
water for seven days, followed by fourteen days of regular drinking water. This regime was
repeated twice with1%DSS, and the mice were euthanized18 days after the final cycle. The
disease activity index was calculated as described above.
3.3.5 Histopathological Colitis Score
Formalin-fixed whole colon tissues were embedded in paraffin, sliced into five μm
thick sections, and stained using hematoxylin and eosin (H&E). Light microscopy (×40
magnification) of four randomly chosen, non-overlapping fields were used to analyze the
stained sections, which were assigned a colitis severity score by an examiner using methods
described previously [62, 115] In short, the degree of colitis was scored based on the
following parameters: extent of the injury (0, none; 1, mucosa; 2, mucosa and submucosa;
and 3, transmural), inflammation severity (0, none; 1, mild; 2, moderate; and 3, severe),
and crypt damage (0, none; 1, basal one-third damaged; 2, basal two-thirds damaged; 3,
crypt loss and the presence of surface epithelium; and 4, loss of the entire crypt and
epithelium). Then the scores for each of these parameters mentioned above were multiplied
by an extent score that represented the percentage of each parameter that had a given
feature as follows: 1, 0−25%; 2, 26−50%; 3, 51−75%; and 4, 76−100%. We defined the
total score as the sum of the three parameters. The bottom limit overall colitis score was 0;
the upper limit totals 12.
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3.3.6 Characterization of CD4+ T cells in the mesenteric lymph node (MLN) and Spleen
For flow cytometry, the mesenteric lymph nodes (MLN) and spleens were pooled
from each group of mice and placed in ice-cold medium. These tissues were mechanically
disrupted, teased into single-cell suspensions, filtered through a cell strainer (70 μm), and
placed in complete medium (RPMI-1640 containing 10% of heat-inactivated fetal bovine
serum). The isolated cell suspension was stimulated with a cell stimulation cocktail
(eBioscience™) plus protein transport inhibitors (Invitrogen, catalog #00-4975) for 4-6
hours. Stimulated cells (1x10⁶) were incubated with anti-CD4 mAb and anti-CD25 mAb
for 15 min on ice (Biolegend, USA). For intracellular cytokine staining, the cell suspension
was incubated with anti-IFNγ (Th1), IL-17 (Th17) after treating the cells with a
Fixation/permeabilization kit (BD Biosciences Catalog # 554714). For T-reg identification,
we used the Foxp3/Transcription Factor Staining Buffer Set (eBioscience Invitrogen)
before adding anti- Foxp3. Staining and washing were carried out in complete medium on
ice. The stained cells were analyzed with a Beckman Coulter FC500 flow cytometer.
3.3.7 Enzyme-linked immunosorbent assays
Interleukin-17 (IL-17), Interleukin-6 (IL-6), Interleukin-10 (IL-10), Interleukin-4
(IL-4), Interleukin-6 (IL-6), Interleukin-1β (IL-1β), Transforming growth factor-beta 1
(TGF-β1), Tumor necrosis factor-alpha (TNF-ɑ) and Interferon-gamma (INF-γ), in the
plasma and/or in colonic tissue lysates were quantified by ELISA kits (R&D Systems,
Minneapolis, MN, USA) following the manufacturer’s recommendations. Colon tissues
were prepared for ELISA, as described previously [114]. Briefly, the mouse colons were
washed immediately with cold phosphate-buffered saline and frozen at -70C° until use.
The samples were homogenized in 200 µl protein analysis buffer (10 mL of 1M tris-
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hydrochloric acid (pH=8.0), 6 mL of 5M sodium chloride and 2 mL of Triton X-100 to 182
mL of sterilized distilled water) [114] in 2 ml microcentrifuge tubes with a 0.9-2.0 mm
stainless steel bead blend and homogenized with a tissue homogenizer (MP FastPrep-24)
at a speed of 0.4 m/s for 20 seconds. Samples were frozen and thawed and homogenized
three times, then centrifuged at 30,000 × g for 30 minutes at 4°C. The supernatant was
collected, and the pellet was re-suspended in phosphate buffer. Protein concentrations were
determined using a bicinchoninic acid assay (Bio-Rad). Samples were frozen until the
ELISA assays were performed, and 0.5-1.0 mg/ml of protein was used for each run,
depending on the interleukin type.
3.3.8 Immunohistochemistry
Immediately following disease scoring, colon tissue was fixed in 10% buffered
formalin (Thermo Fisher Scientific, Waltham, MA) and paraffin-embedded by standard
methodology. Five cm sections were cut and placed on poly-L-lysine coated slides.
Deparaffinizing and antigen retrieval (HIER) was performed, followed by blockage of
endogenous peroxidase activity with 0.3% hydrogen peroxide in methanol for 40 minutes.
After washing with PBS twice, sections were then blocked for 30 minutes with Background
Buster (Innovex Biosciences, Richmond, CA) following the manufacturer’s instructions
and stained with antibodies in the appropriate 10% normal serum. Immunocomplexes were
detected with horseradish peroxidase-conjugated secondary antibodies in 10% normal
serum and ImmPACT DAB (Vector Laboratories, Inc., Burlingame, CA). Sections were
counterstained with hematoxylin (Millipore Sigma, St. Louis, MO) and mounted with
paramount. Images were acquired using a Leica DM2500 optical microscope (Leica
Microsystems, Buffalo Grove, IL). The analysis was done using ImageJ 1.52e (NIH),
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flowing the protocol described by Daniele et al., 2013[195]. Final images were generated
with ImageJ 1.52e (NIH).
3.3.9 Western blot analysis
Colon tissue protein was prepared, as described previously [114]. Samples were
separated using a 12% SDS polyacrylamide gel and transferred onto a nitrocellulose
membrane. The membrane was blocked with Intercept blocking buffer (cat #927-70001,
Li-COR, Lincoln, NE, USA) for 1h and then incubated with the primary antibody (1:1000)
overnight at 4 °C. The membrane was incubated with a species-specific secondary antibody
(horseradish peroxidase-conjugated goat anti-rabbit IgG, or goat anti-mouse IgG diluted at
1:20,000) for one h.
3.3.10 Quantitative PCR analysis of gene expression
For mRNA expression analysis, cDNA was made from total RNA as described. A
two-step amplification qRT-PCR was carried out using SsoAdvanced™ SYBR® green
supermix from Bio-Rad (Hercules, CA, USA) with the mouse primers shown in Table
(2.1). The real-time PCR conditions were as follows: initial step at 95°C for 10 sec and
cycles (n = 40) consisted of 30 seconds at 95°C, followed by 30 seconds
annealing/extension at 60°C and a final extension for 30 seconds at 72°C. Data are
normalized to the expression of the reference gene encoding β-actin. Primers were
purchased from Integrated Technologies and from Invitrogen. Melting temperatures ranged
from 56.0 to 64.5 °C. Primer efficiency was measured for each primer set. All reactions
were performed in triplicate. The qPCR experiments were carried out on a CFX96 Touch
Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). Fold changes were
calculated using the 2−ΔΔCT (Livak) method.

59

3.3.10 Statistical analysis
Mann-Whitney test was used for the determination of statistical significance. P
<0.05 was selected as the level of significance. Data are expressed as mean ± S. E. M. In
the figures section, data are displayed as Grouped -plot summary data, and Column Scatter
plot, with the mean and S.E.M., marked as a line. All calculations were performed using
GraphPad Prism Plot Software 7.03.
3.4 Results
3.4.1 H. hepaticus reduced the effects of DSS:
Experiments were performed on female mice using a high dose of DSS (3%) for a
short duration (9 days) and a low dose (1%) for a longer duration (26 days). Results for the
short-term treatment (acute response) are shown in figures 3.1 and 3.3. H. hepaticus alone
caused little effect on colitis symptoms, whereas diarrhea, stool blood, and weight loss
scores were all reduced by H. hepaticus infection in DSS-treated animals compared with
DSS treatment alone. Colon length was also not reduced as much in the Hh/DSS group
compared to the DSS group. With regard to histopathology, gland dilation, destruction,
atrophy, and abscess were reduced in the Hh/DSS group compared with the DSS group.
Nonetheless, the Hh group did display some colon pathology. The total pathology score
represents a composite of the pathology shown in the adjacent graph. Some proinflammatory cytokines in plasma were elevated in the Hh group (Figure 3.1, panel C), yet
these cytokines were decreased in Hh/DSS compared to DSS. Importantly, the antiinflammatory cytokine IL-10 was increased in Hh/DSS compared to DSS.
Consistent with plasma cytokine results, mesenteric lymph node (MLN) T cell
populations and gene expression were shifted to a less inflammatory profile in Hh infected
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mice (Figure 3.2). Although Il10 expression was not elevated by Hh alone, Foxp3
expression was elevated, suggesting that the immune system was primed for a Treg
response and the Treg population was higher in both Hh and Hh/DSS than control. Il17
and Rorc were sharply decreased in Hh/DSS vs. DSS.
The longer (chronic low dose) DSS treatment resulted in similar reductions in
colitis symptom scores, but colon pathology was not reduced by Hh (Figure 3.3). Effects
on T cell populations were also similar, with reduced Th17 and increased Treg populations.
Absolute numbers of Th17 cells were unaltered among groups, but Treg numbers were
decreased in the DSS group compared to control, but was not substantially reduced in the
Hh/DSS group.
We performed gene expression analysis of colon and MLN tissue (Figure 3.2).
Colon Il17 expression is not increased by H. hepaticus infection alone and the increase in
Hh/DSS vs. control is modest. On the other hand, Il17 expression is strongly increased by
DSS. Conversely, Il10 is more greatly expressed in Hh/DSS than in DSS. Expression of
Rorc, a regulator of Th17 development, and Foxp3, a regulator of Treg development,
largely mirror these trends, although Foxp3 is increased by H. hepaticus alone, indicating
that the immune system is primed for a Treg response. The same IL17 and IL10 trends hold
true in the MLN and flow cytometry data confirm a shift towards a Treg response in H.
hepaticus-infected mice (Figure 3.2).
3.4.2 H. hepaticus caused baseline inflammation without clinical symptoms
To determine the effects of chronic H. hepaticus infection, we followed infected
male and female mice for approximately two months. Neither male nor female mice
developed diarrhea or stool blood (data not shown); however male mice showed delayed
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weight gain compared to controls (Figure 3.4). On the other hand, colon sections of H.
hepaticus-infected mice displayed baseline inflammation. More severe pathology occurred
in male mice than female mice, as has been noted previously [196].
3.4.3 H. hepaticus prevented adenoma formation in the AOM/DSS colon cancer model
To determine whether H. hepaticus infection alters inflammation-associated colon
cancer development, female mice were injected with AOM and treated with three cycles
of DSS. The H. hepaticus-infected group consistently displayed less diarrhea than the
uninfected group and weights remained stable (Figure 3.5). At the end of the experiment,
histopathology scores trended lower, but differences were not significant. Nonetheless,
both total polyp numbers and large polyps were reduced in H. hepaticus-infected mice.
Next, we examined E-cadherin and β-catenin levels in colon tissue. Total E-cadherin did
not differ when measured by Western blot, but immunohistochemistry revealed that Ecadherin at the epithelial surface was increased to normal levels by H. hepaticus infection.
On the other hand, total β-catenin and the ratio of total β-catenin to phospho-β-catenin were
significantly reduced by H. hepaticus (Figure 3.6).
3.5 Discussion
H. hepaticus was initially discovered in 1992 in association with hepatitis and liver
tumors in some strains of mice [197, 198]. The primary colonization site is the caecum and
colon, both in strains of mice that develop liver lesions, and mice resistant to such lesions
[37]. H. hepaticus has not been isolated from human inflammatory bowel disease patients;
however, nested PCR studies report the presence of H. hepaticus in patients with liver
disease[199-201]. After H. pylori, H. hepaticus is the most studied Helicobacter species,
particularly for studying the role of Helicobacter in colitis. Numerous studies of H.

62

hepaticus have been carried out on immunologically abnormal mice, including IL-10-/colitis-prone strains, Rag2(-/-), and Apc(Min/+) mice[50-53, 180, 202, 203]. Several in
vitro studies have been performed to examine virulence factors and the interactions of
epithelial cells with H. hepaticus examine its role in triggering inflammation and immune
response [204-206].
We demonstrated that in immunocompetent mice, H. hepaticus significantly
reduced the histopathological effects of DSS. At the same time, H. hepaticus infection in
the absence of DSS treatment induced baseline pathology, particularly in male mice. Thus,
H. hepaticus can be pathogenic or protective, depending on the circumstances.
DSS normally induces a Th17 response, but H. hepaticus induced IL-10 antiinflammatory cytokines. Danne, et al. discovered that H. hepaticus produces an abundant
polysaccharide that can activate anti-inflammatory macrophages and induce IL-10 [207].
This may explain why we could detect high levels of IL10 in colon tissue but not in plasma.
Xu, et al. studied the role of transcription factor and determined that H. hepaticus can be
both pathogenic and non-pathogenic in immune-competent mice; they found that
H.hepaticus can induce a Th17 response in IL10-deficient mice, but the bacteria would
activate a repressor the th17 transcription factor RORCγ in the same mice[65, 208].
It is well established that different commensal bacterial species have distinct effects
on the intestinal T cell population. For example, segmented filamentous bacteria (SFB)
strongly induce Th17 cells in the small intestine [209-211]. On the other hand, some
bacteria can increase the frequency of colonic Foxp3+ regulatory T (Treg) cells like
Clostridium clusters XIVa and IV [212, 213] or altered Schaedler flora which represents a
community of eight bacterial species [214]. Additionally, some previous studies have
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recognized that Helicobacter species are important inducers of antigen specific Treg cells
during homeostasis [215, 216].
Essential to homeostasis, activation of pattern-recognition receptors (PRRs)
triggers the assembly of pro-inflammatory mediators, like IL-6 and TNFα; however,
additional feedback mechanisms and anti-inflammatory signals, like IL-10, stop chronic
inflammation and tissue injury. On the other hand, the Interactions between gut microbiota
and the host’s immune cells play a crucial role in shaping immune responses and intestinal
health. H. hepaticus is a member of mouse gut microbiota that's tolerated by the host;
however, it will induce colonic inflammation in mice in the absence of an intact IL-10
signal. A polymorphism in IL10 is linked to inflammatory bowel diseases (IBDs) in
humans. While most previous studies have focused on pro-inflammatory properties of H.
hepaticus, there have been hints that H. hepaticus can play an anti-inflammatory role. For
example, Danne et al. report that a polysaccharide produced by H. hepaticus induces
macrophages to secrete IL-10 via Toll-like receptor 2 (TLR2) signaling [64].
Another study found that Tregs specifically recognizing an H. hepaticus peptide
suppress Th17 cells and ameliorate colitis following adoptive transfer [Xu, 2018]. These
findings are complementary to our results in suggesting that H. hepaticus uses induction
of Tregs to promote tolerance.H. hepaticus secretes a polysaccharide that signals through
to induce IL-10 production [64]. Therefore, the effects of H. hepaticus bacteria on the T
cell populations could result from several mechanisms, including effects on macrophages,
the presence of anti-inflammatory peptides, or other mechanisms. H. hepaticus encodes a
cytolethal distending toxin that is a putative virulence factor but could encode additional
anti-inflammatory molecules as well.
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H. hepaticus has previously been shown to induce several types of cancer, but these
studies were carried out in genetically abnormal mice. For example, H. hepaticus induces
CRC in 129SvEv/Rag2−/− mice [50, 93] and increases multiplicity and malignancy of
intestinal polyps in the ApcMin/+ mouse model by a TNF-α-dependent mechanism. H.
hepaticus infection was found to trigger mammary tumorigenesis in ApcMin/+ in the absence
of IBD [217]. Our finding that H. hepaticus induces some baseline pathology, yet skews
the response to DSS towards a Treg-dominated status is consistent with the hypothesis that
H. hepaticus-mediated effects are dependent upon the host immune system.
In summary, our studies suggest that H. hepaticus reduces the severity of DSSinduced colitis via increased Treg induction and that this reduction in inflammation
contributes to reduced or delayed polyp development. These results suggest that H.
hepaticus infection could make humans less prone to inflammatory bowel disease. More
studies need to be done to explore the different virulence factors of this bacteria and how
these organisms influence inflammatory bowel disease in humans.
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Figure 3.1. Acute 3% DSS response. Panel A, colitis symptom scores. Panel B,
colon length and histopathology scores. . Panel C, plasma cytokine levels. Ctrl,
untreated; Hh, H. hepaticus-infected; Hh/DSS, H. hepaticus plus DSS. *, P<0.05;
**, P ≤ 0.01; ***, P ≤0.001.
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Figure 3.2. Panel A, Flow cytometry analysis of mesenteric lymph node cells.
Th17 cells were identified by IL-17 and CD4 staining. Treg cells were identified
by CD4, CD25, and FoxP3 staining. Panel B, Expression of Th17 and Tregassociated genes in colon tissue. Gene expression was determined from total
cDNA using qRT-PCR and values were normalized to the control group.
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Figure 3.3. Chronic treatment with 1% DSS. Panel A, colitis symptom scores.
Panel B, % weight loss, colon length and histopathology scores. Panel C, Flow
cytometry analysis of mesenteric lymph node cells. Th17 cells were identified
by IL-17 and CD4 staining. Treg cells were identified by CD4, CD25, and
FoxP3 staining. Ctrl, untreated; Hh, H. hepaticus-infected; Hh/DSS, H.
hepaticus plus DSS.
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Figure 3.4. Effects of chronic H. hepaticus infection on male and female mice.
Panel A, colitis symptom scores, colon length and histopathology scores for male
animals. Panel B, colitis symptom scores, colon length and histopathology scores
for female animals. *, P<0.05; **, P ≤ 0.01; ***, P ≤0.001.
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Figure 3.5. Effects of H. hepaticus following treatment with AOM and DSS.
Panel A, colitis symptom scores. Panel B, polyp number and histopathology
scores. Panel C, Adenoma Development animal number; Ctrl, untreated; AD,
AOMDSS treated mice; Hh/AD, H. hepaticus plus AOMDSS. *, P<0.05; **, P ≤
0.01; ***, P ≤0.001.
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Figure 3.6. Effects of H. hepaticus on E-cadherin and β-catenin. Panel A, western
blot of β-catenin, Phospho-β-catenin. Panel B, E-cadherin IHC. *, P<0.05; **, P ≤
0.01; ***, P ≤0.001.
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CHAPTER 4

ENTEROHEPATIC HELICOBACTER (EHH) SPECIES MODULATE
COLONIC INFLAMMATION AND COLITIS-ASSOCIATED COLON
TUMORIGENESIS IN MICE3

3

Raheem Alkarkoushi, Yvonne Hui , Haider Rasheed, Prakash Nagarkatti , Mitzi
Nagarkatti , Ioulia Chatzistamou , and T.Testerman. To be submitted to Helicobacter.
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4.1 Abstract
Enterohepatic Helicobacter (EHH) species are gram-negative bacteria that colonize
the colons and sometimes the biliary ducts of humans, primates, rodents, and other
mammals. Though ~20% of the human population may be infected, EHH species are
poorly studied in humans. One EHH species, H. hepaticus, causes colitis in mice with
severe immunologic abnormalities; however, virtually nothing is known about the
influence of EHH species on colitis in wild-type mice, which are more relevant to humans.
Dextran sulfate sodium (DSS) treatment and DSS plus azoxymethane (AOM) are widely
used mouse models of chemically induced ulcerative colitis and colitis-associated colon
cancer. We hypothesized that certain EHH species would alter the course of DSS-induced
colitis and colitis-associated tumorigenesis in mice. We infected C57BL/6 mice with
human- and rodent-associated EHH species +/- DSS, or +/- DSS, AOM, and measured the
effects by measuring colon pathology and inflammation markers. We found that H. cinaedi,
H. pullorum, and H. fennelliae exacerbated DSS-induced colitis and delayed recovery,
whereas H. hepaticus reduced the severity of DSS-induced colitis and hastened recovery.
Concentrations of pro-inflammatory and anti-inflammatory cytokines in plasma and colon
homogenates differed depending on the infecting Helicobacter species. Therefore, EHH
species alter susceptibility to DSS-induced colitis and AOM/DSS colon cancer. These
results suggest that EHH species could make a human more or less prone to inflammatory
bowel disease and could alter the efficacy of treatments.
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4.2 Introduction
Helicobacter pylori were discovered in 1982 and subsequently found to cause
gastric ulcers, cancer, and some extragastric diseases [36, 55]. The discovery of H. pylori
spurred interest in other spiral microorganisms that were found in several animal species,
leading to the expansion of the Helicobacter genus. The genus Helicobacter contains many
intestinal species that are associated with various forms of inflammatory bowel disease in
humans and other mammals [62, 218]. Species that primarily colonize the colon and/or
biliary tract are referred to as enterohepatic Helicobacter (EHH) species. One EHH species,
Helicobacter hepaticus, induces severe colitis in mice with defects in cytokine or T-cell
functions [49-53], Helicobacter bilis [54]also has been reported to cause colitis mice, while
other EHH species, such as Helicobacter cinaedi and Helicobacter fennelliae, are
associated with colitis in humans [55]. There are no diagnostic tests for EHH species, and
they are extremely difficult to culture from feces. EHH species in humans are most often
detected in cases of sepsis or infection of normally sterile sites[219-221]. Therefore,
research on EHH species has lagged, and we do not have a clear outline of their roles in
gastrointestinal pathogenesis or how environmental and/or host factors could increase their
pathogenesis. Studies that have identified associations between EHH species and
inflammatory bowel disease (IBD) have mostly used genus-specific PCR detection [222224], precluding determination of which species are most associated with disease.
Inflammatory bowel disease (IBD), which encompasses ulcerative colitis (UC) and
Crohn’s disease (CD), is a complex multifactorial disease [14]. Both UC and CD are
chronic or relapsing conditions that involve inflammation of the intestine. Triggers of IBD
likely include various combinations of environmental, psychological, and genetic
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components, as well as intestinal dysbiosis [43, 225-229]. Immune system regulation,
including the balance between T helper 17 (Th17) cells and regulatory T cells (Treg), is
also important for intestinal homeostasis [90], as is an intact mucosal barrier [226].
Dextran sulfate sodium (DSS)-elicited colitis is a well-established animal model of
mucosal inflammation that has proven useful for studying various aspects of IBD
pathology, immunology, and environmental factors [230]. It is also used to test potential
IBD treatments [231, 232]. The mechanism by which DSS induces intestinal inflammation
is unclear but is likely the result of damage to the epithelial monolayer lining the large
intestine, allowing the dissemination of proinflammatory intestinal contents [187]. The
severity and chronicity of colitis can be modulated by changing the concentration of DSS
and the treatment schedule [100].
When using animal models as proxies for human disease, it is preferable to use
human pathogens; however, not all human pathogens infect laboratory mice or cause
similar diseases. To establish mice as a suitable species for studying human EHH infection,
we sought to compare the rodent-associated species H. muridarum and H. hepaticus with
three of the most common human-associated EHH species, H. cinaedi, H. pullorum, and
H. fennelliae. Helicobacter muridarum was initially described as a member of the normal
flora of conventional rodents [59]. Subsequent studies, however, showed that H.
muridarum could induce colitis and gastritis in mice, confirming a pathogenic role for this
species [60-62]. We examined the effects of these species on colon pathology and the
immune response with and without DSS treatment.
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We found that all tested species colonized mice for the duration of the experiments.
All caused some degree of inflammation detectable by histology, but only H. muridarum
and H. cinaedi substantially worsen colitis symptoms following DSS treatment. Since H.
cinaedi is also the enterohepatic species most often associated with severe disease in
humans, the mouse model may be an appropriate model to study the potential effects of
EHH species in humans.
4.3 Materials and methods
4.3.1 Mice: Female and male C57BL/6 mice (aged 8-10 weeks) were purchased from the
(Jackson laboratory). All mice were housed at the AAALAC-accredited animal facility at
the University of South Carolina, School of Medicine (Columbia, SC). All procedures were
performed according to NIH guidelines under protocols approved by the Institutional
Animal Care and Use Committee. Animals were housed in a controlled environment (12 h
daylight cycle) with food and water ad libitum. All the animal experiments are done
according to the ARRIVE guidelines for reporting experiments involving animals[189,
190]. After 1 week of acclimation on a normal chow diet, the mice were randomly divided
into the groups we planned for each experiment. The Helicobacter species groups received
200µl of live bacteria suspended in saline at a concentration estimated to be 1 x 109 cfu/ml.
4.3.2 Bacterial strains, cultivation, mice infection and infection confirmation
Helicobacter species used in this study are H. hepaticus ATCC51448, H. cineadi
ATCC-BAA847, H. fennelliae ATCC35684, and H. pullarum ATCC51864. These bacteria,
were purchased from (ATCC) and were cultured in a humidified environment at 37°C with
5% CO2, in Ham’s F-12 medium containing 2% fetal calf serum in 25-cm2 tissue culture
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flasks containing 5 to 7 ml of medium or in 75-cm2 tissue culture flasks containing 15 to
20 ml of medium. H. muridarum bacteria were passaged every 2 to 3 days. After
microscopically verifying appropriate morphology and motility, cultures were centrifuged
at 25°C at 4500 rpm for 20 minutes, then the pellet suspended in 3 ml saline. The BacTiterGlo Microbial cell viability assay from Promega was used to confirm the density and
viability of the bacteria after the gavage as previously described [Testerman, 16672389].
Infection was repeated every other day for a total of four inoculations.
Infection was confirmed by performing PCR on DNA from the stool. Helicobacter
genus-specific 16S primers (H276F, H676R) ), which amplify an ~700 bp conserved region
of the 16S rRNA, as previously described [233] were used. For some experiments and/or
samples we used Helicobacter muridarum 16S rRNA species-specific primers (H. mur.
p30F, H. mur. p30R ), which amplify an ~800 bp conserved region of the 16S rRNA and/or
H. hepaticus-specific primers (p25R, p25F), which amplify a ~350-400 bp conserved
region of H. hepaticus, as previously described [113]. These primers were used to confirm
that there was no contamination between the groups of the experiments. Fecal samples
were collected and stored at -80 C until they were used for analysis. Fecal DNA was
obtained using the Omega EZNA stool DNA extraction kit according to the manufacturer’s
recommendations then fecal PCR was performed.
4.3.3 Induction of colitis with dextran sulfate sodium (DSS).
1-3 % of DSS (Chem-Impex Int’l Inc., MW ~40000 ) was given in drinking water
to previously infected mice for 8-10 days. The amount of DSS taken, weight, diarrhea
score, and blood score were recorded daily. The disease activity index was calculated as
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previously described[114, 115]. We determined the DAI using the following variables:
stool blood (0, negative; 1, occult blood positive; 2, rusty; and 4, gross bleeding), changes
in weight (0, <1%; 1, 1−5%; 2, 6−10%; 3, 11−15%, and 4, >15%), and stool consistency
(0-1, normal; 2-3, loose stools; and 4, diarrhea).
4.3.4 AOM/DSS model of Colitis-Associated Cancer
Mice were injected intraperitoneally with 10 mg/kg of azoxymethane (AOM ) (1
mg/ml in isotonic saline, diluted from 10 mg/ml stock solution in dH2O stored at -20°C) to
induce colon cancer [193, 194]. One week later, 2% DSS was administered via drinking
water for seven days, followed by fourteen days of healthy drinking water. This regime
was repeated twice with1%DSS, and the mice were euthanized18 days after the final cycle.
The disease activity index was calculated as described above.
4.3.5 Colonoscopy, and colonoscopy scoring
In the day before the sacrifice, the mice were anesthetized in a controlled isoflurane
vaporizer chamber (5% isoflurane with 75% CO2/25% O2). The evaluation of colitis or
colorectal cancer was done by performing colonoscopy at the end of the experiment with
all groups using a Karl Storz endoscope (Tuttlingen, Germany). Colonoscopy scores were
determined using a scoring system previously published [234, 235].Table 4.1.
Colonoscopy scores were Colorectal cancer endoscopy was scored the following
way: 0 = normal colon, 1 = presence of blood and tissue sloughing, 2 = presence of 1-2
colonic polyps, 3 = 3-5 colonic polyps present, 4 = 5-10 colonic polyps present, 5 = <10
polyps present in the colon.[235]
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4.3.6 Histopathological Colitis Score
Formalin-fixed, paraffin-embedded whole colon tissues were sliced into 5 μm thick
sections and stained using hematoxylin and eosin (H&E). Light microscopy (40x
magnification) with four randomly chosen, non-overlapping fields were used to analyze
the stained sections, which were assigned a colitis severity score by an examiner using
methods described previously[115, 236]. In short, the degree of colitis was scored on the
basis of the following parameters: extent of injury (0, none; 1, mucosa; 2, mucosa and
submucosa; and 3, transmural), inflammation severity (0, none; 1, mild; 2, moderate; and
3, severe), and crypt damage (0, none; 1, basal one-third damaged; 2, basal two-thirds
damaged; 3, crypt loss and the presence of surface epithelium; and 4, loss of the entire
crypt and epithelium). Then the degrees for each of these aforementioned parameters were
multiplied by an extent score that represented the percentage of each parameter that had a
given feature as follows: 1, 0−25%; 2, 26−50%; 3, 51−75%; and 4, 76−100%. We defined
the total score as the sum of the three parameters.
4.3.7 Enzyme linkage immunosorbent assays
Interleukin-17 (IL-17), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-1β
(IL-1β), transforming growth factor beta 1 (TGF-β1 ), tumor necrosis factor-alpha (TNFɑ)
and interferon gamma (IFNγ) in plasma and in colonic tissue lysates were quantified by
ELISA kits (R&D Systems, Minneapolis, MN, USA) following the manufacturer’s
recommendations.
Colon tissues were prepared as described previously[114]. Briefly, the mouse
colons where washed with cold phosphate buffer saline during the sacrifice time and froze
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at -70 till the time of the process. The samples were homogenized in 200 µl protein analysis
buffer (10 mL of 1M tris-hydrochloric acid (pH=8.0), 6 mL of 5M sodium chloride and 2
mL of Triton X-100 to 182 mL of sterilized distilled water)[114] in 2 ml Eppendorf Safe
lock microcentrifuge tubes with homogenizer beads using an MP FastPrep-24 (0.4 m.s for
20 seconds). Then the samples were frozen and thawed; this process repeated three-times.
Finally, the samples were centrifuged at 30,000 × g for 30 minutes at 4°C. The supernatant
was collected, and the pellet was re-suspended again in phosphate buffer, the process of
frozen and thawed and homogenization repeated between each cycle. BCA assay (BioRad) was used to determine protein concentrations determinations. Samples were frozen
until the ELISA assays were performed. The protein concentrations used for the ELISA
was 0.5-1.0 mg/ml depending on the interleukin type being assayed.
4.3.8 Statistical analysis
The Mann-Whitney test was used for the determination of statistical significance.
P <0.05 was selected as the level of significance. Data are expressed as mean ± S. E. M.
All calculations were performed using GraphPad Prism Plot Software 7.03.
4.4 Results
4.4.1 Baseline Infection
We infected male and female C57BL/6 mice with 5 Helicobacter species (H.
cinaedi, H. pullorum, H. fennelliae, H. muridarum, H. hepaticus) to determine whether
they cause baseline pathology. As shown in figure (4.1), these species cause minimal
clinical symptoms. Reductions in weight gain were more prominent in male mice than in
female mice. On the other hand, examinations of the colons revealed pathology caused by
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these species.

Colon lengths trended shorter and there was significantly more

histopathology (Figure 4.2). Inflammation and mucosal damage were greater in males than
in females. Male control mice had slight amounts of inflammation, whereas females did
not.
4.4.2 Enterohepatic Helicobacter species differ in their abilities to exacerbate DSSmediated colitis
We next examined the effects of these species during an acute DSS treatment and
during a recovery period following treatment. H. cinaedi and H. fennelliae caused a more
rapid rise in diarrhea scores than DSS alone, although this effect was only sustained for H.
cinaedi. H. pullorum caused less diarrhea overall than DSS alone. H. cinaedi also caused
a more rapid increase in stool blood, while the other species did not appreciably differ from
DSS. The most dramatic effects were seen during the recovery phase. There was residual
stool softening and bleeding in most Helicobacter-infected groups. More importantly,
colon pathology had not resolved in Helicobacter-infected mice, except for those infected
with H. hepaticus, whereas most mice treated with DSS alone had normal histopathology
at that time (Figure 4.3).
In addition, some plasma and colonic inflammatory markers remained elevated at
the end of the experiments. Plasma IL-17 was substantially elevated in H. cinaedi-infected
mice compared with controls or DSS only, whereas plasma IL-6 was elevated in H.
fennelliae-infected mice (Figure 4.4). Serum amyloid A was reduced by H. hepaticus, but
SAA levels were similar to the DSS group in groups infected with other Helicobacter
species. A similar pattern was seen in colon tissue. H. fennelliae elevated IL-6 in the colon,
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while levels of IL-17 and TNFα were higher in H. cinaedi-infected mice. H. hepaticus
showed a less inflammatory pattern with increased IL-10.
We also tested the effects of Helicobacter species during chronic, low dose (1%)
DSS treatment. H. muridarum, H. cinaedi, H. fennelliae and H. pullorum all increased the
stool blood scores and disease activity scores (Figure 4.5). Effects on diarrhea were modest.
Colon lengths and colon pathology were similar compared to DSS treatment only.
4.4.3 H.cineadi increased mortality, but did not hasten polyp development
IBD increases the risk of colorectal cancer (CRC) in humans. This is presumably
due to chronic inflammation, but the the precise factors contributing to development CRC
in IBD patients are poorly understood[237-239]. In one of the previous experiments, we
found dysplasia in one H. cinaedi-infected mouse colon. Therefore, we sought to determine
whether two cycles of DSS might further increase dysplasia. We did not find dysplasia;
however, colitis symptoms and pathology were consistently more severe in H. cinaediinfected mice treated with mice compared to DSS alone (figure 4.6).
We then proceeded to test the effects of H. cinaedi in the AOM/DSS model of
inflammation-associated CRC development. As with previous experiments, symptom
scores tended to be more severe in H. cinaedi-infected animals (figure 4.7). In fact, more
than half of the H. cinaedi-infected mice died or required euthanization prior to the end of
the experiment. This may have affected the ultimate outcome of the experiment.
Colonoscopies performed shortly before the end of the experiment revealed more severe
inflammation in the Hc/AD group than in the AD group. The number of polyps was similar
between the infected and uninfected animals, indicating no measurable increase in
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tumorigenesis due to H. cinaedi. Again, the number of surviving animals was lower in the
H. cinaedi group.
4.5 The discussion
Enterohepatic Helicobacter species are associated with several diseases in humans
[35,36]. Many reports connect these bacteria with diarrhea, proctitis, colitis, and sepsis
[240-250]. H. hepaticus and H. bilis are most often associated with biliary tract disorders
such as cholecystitis, liver or gall bladder cancer, or chronic pancreatitis [199, 245, 251253]; Nonetheless, little is known about their pathogenesis. Some, but not all, EHH species
have genes encoding cytolethal distending toxin (CDT; cdtABC) [254, 255]. Even when
present, this gene may not be expressed or active in all strains [86]. On the other hand,
most EHH species lack the urease enzyme, which is critical for H. pylori colonization.
Therefore, animal models are needed to explore EHH virulence factors. Our study paves
the way for future virulence studies by establishing the effects of three human-associated
species on colon pathology and susceptibility to DSS-induced colitis.
4.5.1 H. hepaticus reduced the histopathological effect of DSS in wild-type mice
H. hepaticus was discovered in 1992 in association with

hepatocellular

nonmalignant neoplasm and glandular cancer in some strains of mice [197, 198]. The
primary sites of colonization are the caecum and colon [256]. H. hepaticus has not been
isolated from human inflammatory bowel diseases patients. However, nested PCR studies
report the presence of this bacteria in patients with liver disease [199-201]. H. hepaticus
has received the most attention after the H. pylori and has become the prototype organism
for studying the role of Helicobacter species in colitis. Many studies use it with different
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types of immune deficient mice, including IL-10-/- colitis-prone mice, Rag2(-/-)
Apc(Min/+) mice, and in an adoptive T cell transfer model with Rag2-deficient mice [4953, 93, 202, 203, 217]. Moreover, many in vitro studies of H. hepaticus virulence factors
and their interactions with epithelial cells demonstrate that this bacteria triggers
inflammatory immune responses [204, 205, 255]. In contrast, our results demonstrate the
role of H. hepaticus in lowering DSS-induced colitis with statistically significant effects.
Moreover, our data indicate that H. hepaticus induces IL-10 rather than IL-17. Our data
may be explained by production of a large polysaccharide that can induces antiinflammatory responses in macrophages and production of IL-10, which was reported by
Danne et al. [207]. Our results are also consistent with those of Xu et al., who found that
Tregs specific for an H.hepaticus epitope are strongly anti-inflammatory [65, 208].
4.5.2 Several human-associated Helicobacter species exacerbate DSS induced colitis.
H. cinaedi, H. pullorum, and H. fennelliae are among the Helicobacter species most
commonly isolated from extragastric sites. Helicobacter pullorum was first reported in
broiler chickens and humans with enterocolitis in 1994 [241, 242] and has since been
associated with hepatobiliary diseases in humans, mice and chickens [241, 242, 257]. It
has also been isolated from a psittacine (parrot) bird with diarrhea [258], suggesting that
zoonotic transmission from pet birds could occur. It was reported that H. pullorum is
internalized by and activates murine macrophages, stimulating the expression of proinflammatory cytokines like TNF-α, IL-1β, IL-6 and murine MIP-2. Moreover, H.
pullorum was shown to activate inducible nitric oxide synthase (iNOS) [259]. H. pullorum
adheres to and invades human viscus Caco-2 cells, possesses a type VI secretion
system[260], and expresses cytolethal distending toxin (CDT) [86, 254, 261]. H. pullorum
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LPS has the best biological activity among the genus Helicobacter in terms of NF-κB
activation [262]. H. pullorum also triggers IL-8 production via NF-κB [263]. Our study is
the first to explore in vivo pathogenicity of H. pullorum. Our data show that H. pullorum
induces pathology in mice, yet has minimal effects on DSS-induced colitis.
Helicobacter cinaedi and H. fennelliae were identified in homosexual men with
chronic diarrhea, enteritis, proctitis, or proctocolitis in the mid-1980s [244, 264]. Many
subsequent reports document bacteremia cases in humans due to H. cinaedi [58]. While H.
fennelliae is most often associated with diarrhea or sepsis, H. cinaedi has been associated
with these diseases along with meningitis [265], atherosclerosis [266], carotid
arteritis[178], cellulitis[267, 268], and osteomyelitis[269]. Infections in patients without
immunodeficiency have also been reported [270-272]. Fox et al. isolated H. cinaedi from
the colon, liver, and mesenteric lymph nodes of a rhesus monkey with chronic colitis and
hepatitis [273].
Despite the clinical importance of H. cinaedi, its virulence mechanisms have not
been completely defined. Shen et al. found that CDT contributes to the virulence of H.
cinaedi in IL10-/- mice and it is able to activate a Th1 immune response in that model
[274]. Alkyl hydroperoxide reductase (AhpC), which is an enzyme that detoxifies alkyl
hydroperoxides, contributes to H. cinaedi colonization of BALB/c and BALB/c IL-10-/mice [275].
H. fennelliae increased colon pathology, but did not exacerbate colitis symptoms,
whereas H. cinaedi caused increases in both symptoms and colon pathology. H. fennelliae
also induced more IL-6, but less IL-17 than H. cinaedi. This could be due to the fact that
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H. fennelliae lacks CDT, while H. cinaedi has the toxin. A previous study found that H.
cinaedi induces colitis in Rag2-/- mice; however, these mice lack functional T and B
lymphocytes [276]. However, since the Th17/Treg axis is a key player in IBD, the Rag2-/model does not completely mimic human IBD and it is important to determine how H.
cineadi interacts with various immune system components.
Enterohepatic Helicobacter species are likely underestimated causes of disease in
humans due to their fastidious growth requirements. Helicobacter species have not been
cultured from human IBD patients, but a role for EHH species in colitis is inferred from
epidemiological studies [222-224]. Since there are no diagnostic tests for EHH species and
studies have used genus-specific PCR primers rather than species-specific primers, the
roles of individual EHH species in human IBD remain obscure. The prevalence of these
species in healthy humans is also unknown. Our study demonstrates that several humanassociated EHH species can colonize mice, but that they differ in their pathogenic
potentials. Therefore, diagnostic methods enabling the correct identification of these
bacteria are needed to help clarify the epidemiology and pathology of these infections in
humans.
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Table 4.1. Scoring form for assessment of colitis and colorectal cancer. [234, 235]
Scores

Parenteral
findings

Wall
transparency

Intestinal bleeding Focal lesion

(Diarrhea,
Blood in
stool,
prolapse)

(Colonic mucosa
transparency)

Anus looks
normal

1

(Any mucosal
bleeding?)

Erosion and
ulcer

Small and large
mucosal vessels
can be seen

No intestinal
bleeding

No lesion

Diarrhea
local clumps

Small mucosal
vessels cannot be
seen

Mild bleeding

Edematous area
of mucosa

2

Bloody anal
discharge

Large mucosal
vessels cannot be
seen

Intermediate
bleeding

Erosion or red
area of mucosa

3

Rectal
prolapse

The thickened
appearance of the
mucosa, blood
vessels cannot be
seen

Spontaneous
bleeding

Ulcer

0
(Normal)

Inflammation scores = ……………………………….
Inflammation + Tumor = ………………………………
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Figure 4.1. Effects of Helicobacter species on male and female mice. Panel A,
colitis symptom scores for male mice. Panel B, colitis symptom scores for female
mice. Ctrl, untreated; Hh, H. hepaticus-infected; Hc, H. cinaedi infected; Hp, H.
pullorum infected; Hf, H. fennelliae infected; Hm, H. muridarum-infected.
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Figure 4.2. Effects of Helicobacter species on male and female mice. Panel A,
colon length and histopathology scores for male mice. Panel B, colon length and
histopathology scores for female mice. Ctrl, untreated; Hh, H. hepaticus-infected;
Hc, H. cinaedi infected; Hp, H. pullorum infected; Hf, H. fennelliae infected; Hm,
H. muridarum-infected. *, P <0.05; **, P ≤ 0.01; ***, P ≤0.001.
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Figure 4.3. Effects of Helicobacter species on recovery from DSS. Panel A,
colitis symptom scores. Panel B, Histopathology scores. Ctrl, untreated; DSS,
DSS treated; Hh/DSS, H. hepaticus plus DSS; Hc/DSS, H. cinaedi plus DSS;
Hp/DSS, H. pullorum plus DSS; Hf/DSS, H. fennelliae plus DSS; Hm/DSS, H.
muridarum-plus DSS. *, P <0.05; **, P ≤ 0.01; ***, P ≤0.001.
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Figure 4.4. Plasma and colon cytokines following recovery from DSS treatment. Panel
A, plasma cytokines. Panel B, colon cytokines. Protein levels were determined by
ELISA using colon homogenates. Ctrl, untreated; DSS, DSS treated; Hh/DSS, H.
hepaticus plus DSS; Hc/DSS, H. cinaedi plus DSS; Hp/DSS, H. pullorum plus DSS;
Hf/DSS, H. fennelliae plus DSS; Hm/DSS, H. muridarum-plus DSS. *, P <0.05; **, P
≤ 0.01; ***, P ≤0.001.
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Figure 4.5. Effects of Helicobacter species during chronic DSS treatment. Panel
A, colitis symptom scores. Panel B, disease activity index and colon lengths.
Panel C, histopathology scores. Ctrl, untreated; DSS, DSS treated; Hh/DSS, H.
hepaticus plus DSS; Hc/DSS, H. cinaedi plus DSS; Hp/DSS, H. pullorum plus
DSS; Hf/DSS, H. fennelliae plus DSS; Hm/DSS, H. muridarum-plus DSS. *, P
<0.05; **, P ≤ 0.01; ***, P ≤0.001.
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Figure 4.6. Effects of H. cinaedi on the response to two cycles of DSS
treatment. Panel A, disease activity index and diarrhea scores. Panel B, stool
blood scores. Panel C, histopathology scores. Ctrl, untreated; DSS, DSS
treated; Hc/DSS, H. cinaedi plus DSS. *, P <0.05; **, P ≤ 0.01; ***, P
≤0.001.
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Figure 4.7. Effects of H. cinaedi following treatment with AOM and three cycles
of DSS. Panel A, disease activity index. Panel B, histopathology scores. Panel C,
colonoscopy images. Panel D, colonoscopy scores. Panel E, survival rate. Ctrl,
untreated; DSS, DSS treated; Hc/DSS, H. cinaedi plus DSS. *, P <0.05; **, P ≤
0.01; ***, P ≤0.001.
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CHAPTER 5

SUMMARY AND CONCLUSIONS
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Helicobacter pylori were discovered in 1982. This microorganism infects over 50%
of the global population. Helicobacter pylori are the main reason for gastritis, peptic ulcers,
and gastric cancer. In 1994, the International Agency for Research on Cancer (IARC)
categorized Helicobacter pylori as a category I carcinogen. The discovery of H. pylori
exaggerated interest in a different spiral microorganism that had been seen in several
animal species. The genus Helicobacter contains many intestinal species associated with
the various forms of inflammatory bowel disease and relates to the development of colitis
in mammalian hosts. Enterohepatic Helicobacter (EHH) species colonize the colons and
sometimes the biliary ducts of humans, primates, rodents, and other mammals. Some of
these poorly studied organisms usually cause persistent, asymptomatic infections, but
occasionally cause intestinal diseases or even cancer in species ranging from rodents to
primates. Based on limited studies, ~20% of the human population may be infected. Several
studies suggest that EHH species contribute to inflammatory bowel disease (IBD) in
humans, and IBD has emerged as a public health challenge worldwide.
Several models of inflammation and inflammatory bowel disease suggest that
bacteria are necessary, but insufficient triggers of IBD; moreover, several studies have
reported that EHH species modulate IBD. As presented in the first study, our experiments
suggest that H. muridarum increases susceptibility to DSS-induced colitis by inducing
macrophage-associated cytokines and creating a mucosal milieu conducive to Th17
polarization. H. muridarum can induce proinflammatory cytokines, yet, the bacteria by
itself is not sufficient to increase colitis symptoms. These data support the two hits
hypothesis to develop IBD.
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I3C, on the other hand, succeed in ameliorates colitis via induction of Tregs. I3C succeed
in the suppression of Th17 cells, and suppression of macrophage-associated
proinflammatory cytokines. The presence of H. muridarum bacteria did not reduce or
change its effect. Interestingly The identities of miRNAs altered by H. muridarum and DSS
were similar to Those seen in colitis studies in both mice and humans. However, the
direction of change was not always consistent. I3C is equally effective in the presence and
absence of H. muridarum. They are warranting further research on the use of I3C or similar
AhR agonists for the treatment of inflammatory bowel disease.
The complexity of the interaction of the host and H. hepaticus becomes obvious
when mice deficient for IL10 signaling (either due to attenuated IL10 receptor signaling,
or IL10 secretion) are colonized with H. hepaticus, which both lead to an exacerbating,
IL17- and IL23-mediated inflammation of the colon and the cecum. Our Data in the second
study, show that H. hepaticus reduced the severity of DSS-induced colitis and hastened
recovery following treatment. H. hepaticus infection increased the T-regulatory cell
percentage in the mesenteric lymph nodes compared to mice treated with DSS only. H.
hepaticus also reduced the number of polyps in the AOM/DSS colon cancer model and
reduced β–catenin activation. The proinflammatory and the anti-inflammatory cytokine
measurements in plasma and colon homogenates indicate an increase of colonic IL-10 and
a reduction in proinflammatory cytokines. Therefore, H. hepaticus bacteria alter
susceptibility to DSS-induced colitis and AOM/DSS colon cancer. These results suggest
that H. hepaticus infection could make humans less prone to IBD. It is truly intriguing that
H. hepaticus (and possibly also other Helicobacter spp) evolved anti-inflammatory
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mechanisms by inducing potent IL10 secretion by host cells to counteract the bacterial
PAMP-mediated proinflammatory effects on the immune system.
Several murine enterohepatic Helicobacter species are used in experimental
systems to study the regulation of host–pathobiont interactions that lead to
histopathological alterations and clinical signs of disease, resembling those observed in
patients with IBD. However, there is no study try to apply human EHH or study their ability
to colonize mice colon. In the third study, we tried to see wither human-associated EHH
species infect mice or not? And how do they compare with H. muridarum and H. hepaticus
in the first and the second studies; finally try to see wither they act via similar or different
mechanisms or not. We compared the degree of pathology among five species of
enterohepatic Helicobacter bacteria: three human-associated species and two mouseassociated species. All enterohepatic Helicobacter species tested can produce low-level
baseline inflammation in the colon. H. cinaedi, H. pullorum, and H. fennelliae exacerbated
DSS-induced colitis and delayed recovery following cessation of DSS treatment. On the
other hand, H. hepaticus reduced the severity of DSS-induced colitis and hastened
recovery, although it still can produce a baseline inflammation. H. cinaedi, the species most
often reported in humans, induced more severe symptoms compared to other EHH species
and reduced the survival rate in the AOM/DSS colon cancer model.
In summary, Inflammatory Bowel diseases IBD such as Colitis and Crohn's
diseases is idiopathic diseases that increase the percentage to develop colorectal cancer in
humans. Moreover, the pathogenesis of IBD and the role of EHH is poorly understood. We
found that certain Helicobacter species are almost certainly involved in IBD pathogenesis,
suggesting that they can be used as models of inflammation and inflammatory bowel
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disease. It suggests that more research needs to be done on enterohepatic Helicobacter
bacteria. First, to determine their roles in human diseases, second to determine the exact
mechanism, finally, to determine the virulence factors of EHH involved in IBD
pathogenesis that remains undiscovered.
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CHAPTER 6

FUTURE DIRECTIONS
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Based on our results, many studies need to be done to determine the mechanisms
of EHH virulence. Genetic studies are needed to identify differences in the virulence
factors between more and less pathogenic species, and between H. pylori and EHH species.
This will be followed by experiments to determine the roles of identified virulence factors.
For example, gamma-glutamyl transpeptidase is a virulence factor found in both H. pylori
and H. muridarum; In H. pylori, this virulence factor leads to cell cycle arrest, necrosis,
and apoptosis. Moreover, the cytolethal distending toxin subunit B (cdtB) is found in some
EHH species, but not H. pylori. We should study the role of each one of these genes and
their proteins. Human studies are needed to measure the prevalence of EHH species and to
isolate human strains for testing in vitro and in vivo. Experiments on wild-type mice need
to be done so we can study the roles of Helicobacter genes using mutant bacteria rather
than the effects of wild-type bacteria in immunologically abnormal mouse strains.
Lastly, it is essential to study the roles of EHH species in humans and to isolate the
bacteria from the human samples. We can search for EHH bacteria in human stool and or
tissue by PCR using primers specific for these bacteria. Determining which unique EHH
proteins would be useful for serological assays is another goal. In the long term, DNA-,
protein-, or antibody-based assays are needed for specific diagnosis of individual EHH
species that are needed since there are currently no available diagnostic tests.
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